###begin article-title 0
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The transcription factor TCF7L2 is an essential factor for glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells. We studied whether a defect in the enteroinsular axis contributes to impaired insulin secretion in carriers of TCF7L2 polymorphisms.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 39 51 <span type="species:ncbi:9606">participants</span>
###xml 108 120 <span type="species:ncbi:9606">participants</span>
###xml 176 188 <span type="species:ncbi:9606">participants</span>
###xml 197 209 <span type="species:ncbi:9606">participants</span>
###xml 302 314 <span type="species:ncbi:9606">participants</span>
###xml 420 432 <span type="species:ncbi:9606">participants</span>
We genotyped 1,110 non-diabetic German participants for five single nucleotide polymorphisms in TCF7L2. All participants underwent an OGTT; GLP-1 secretion was measured in 155 participants. In 210 participants, an IVGTT combined with a hyperinsulinaemic-euglycaemic clamp was performed. In another 160 participants from the Netherlands and 73 from Germany, a hyperglycaemic clamp (10 mmol/l) was performed. In 73 German participants this clamp was combined with a GLP-1 infusion and an arginine bolus.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 521 522 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
The OGTT data confirmed that variants in TCF7L2 are associated with reduced insulin secretion. In contrast, insulin secretion induced by an i.v. glucose challenge in the IVGTT and hyperglycaemic clamp was not different between the genotypes. GLP-1 concentrations during the OGTT were not influenced by the TCF7L2 variants. However, GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in GLP-1-induced insulin secretion in carriers of the risk allele in two variants (rs7903146, rs12255372, p < 0.02).
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
Variants of TCF7L2 specifically impair GLP-1-induced insulin secretion. This seems to be rather the result of a functional defect in the GLP-1 signalling in beta cells than a reduction in GLP-1 secretion. This defect might explain the impaired insulin secretion in carriers of the risk alleles and confers the increased risk of type 2 diabetes.
###end p 8
###begin title 9
Electronic supplementary material
###end title 9
###begin p 10
The online version of this article (doi:10.1007/s00125-007-0753-6) contains supplementary material, which is available to authorised users.
###end p 10
###begin title 11
Keywords
###end title 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 499 508 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR&#947;</italic>
###xml 525 526 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 605 611 597 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KCNJ11</italic>
###xml 628 629 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
Genome-wide scans for diabetes susceptibility genes have been performed in various populations. In early 2006, it was reported that variants in the transcription factor 7-like 2 (TCF7L2) gene were strongly associated with an increased risk of type 2 diabetes in an Icelandic, a Danish and a US population [1]. The estimated population attributable risk of type 2 diabetes of this variation lies between 10 and 25%, which is in the range of the peroxisome proliferator-activated receptor gamma gene (PPARgamma) Pro12Ala (25% [2]) and the potassium inwardly-rectifying channel, subfamily J, member 11 gene (KCNJ11) Glu23Lys (15% [3]) polymorphisms.
###end p 13
###begin p 14
###xml 39 40 39 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 607 613 607 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 713 714 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 719 720 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 877 883 877 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1007 1013 1007 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1291 1297 1291 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1510 1513 1510 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT</italic>
###xml 1593 1596 1593 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCG</italic>
###xml 1685 1687 1685 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1722 1725 1722 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT</italic>
###xml 1774 1780 1774 1780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1470 1474 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
In the initial report of Grant et al. [1], five single nucleotide polymorphisms (SNPs) within introns 3 and 4 of the TCF7L2 gene (rs12255372, rs7903146, rs7901695, rs11196205, rs7895340) were identified to associate with an increased risk of type 2 diabetes. This finding initiated a series of reports in various populations confirming the effect of these polymorphisms within the TCF7L2 gene on the type 2 diabetes risk [4-12]. Recently, the T allele of rs7903146 was identified as the variant that most strongly determines the risk of type 2 diabetes [13]. In carriers of the risk alleles for SNPs within TCF7L2 several studies additionally showed an impaired insulin secretion estimated from an OGTT or IVGTT [6, 7, 9, 10]. These studies indicate that progressive loss of insulin secretion might be the essential component of the phenotype which predisposes carriers of the TCF7L2 variant to develop type 2 diabetes. The pathogenic mechanism of the impaired insulin secretion due to polymorphisms in the TCF7L2 gene is not yet clear. It could be the consequence of a reduction in beta cell mass or could reflect a dysfunction of pancreatic beta cells. Furthermore, a defect in incretin-induced stimulus secretion coupling could mediate a reduction of insulin secretion in carriers of the TCF7L2 polymorphisms. The latter hypothesis is supported by the molecular mode of action of the transcription factor TCF7L2. TCF7L2 is an essential component of the wingless-type MMTV integration site family, member 1 (WNT) signalling pathway, which is crucial for the regulation of the glucagon gene (GCG) expression and the secretion of its product GLP-1 by the intestinal endocrine L cells [14]. Therefore, an alteration in the WNT signalling pathway through polymorphisms in the TCF7L2 gene might result in an altered GLP-1 response, which in turn could lead to a lower postprandial insulin secretion.
###end p 14
###begin p 15
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 190 202 <span type="species:ncbi:9606">participants</span>
To test this hypothesis we analysed the associations of the above-described TCF7L2 polymorphisms with basal GLP-1 secretion and glucose-induced GLP-1 response during an OGTT in non-diabetic participants. We further studied the influence of the TCF7L2 SNPs on insulin secretion kinetics to i.v. administered glucose during an IVGTT and a hyperglycaemic clamp. In addition, we particularly investigated the influence on GLP-1-induced insulin secretion using a combined hyperglycaemic clamp with additional GLP-1 infusion and arginine bolus [15].
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Participants</bold>
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 380 387 380 387 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 387 470 387 470 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18">Anthropometric and metabolic data from all 1,110 participants who underwent an OGTT</p>
###xml 387 470 387 470 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18">Anthropometric and metabolic data from all 1,110 participants who underwent an OGTT</p></caption>
###xml 470 471 470 471 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</th>
###xml 471 480 471 480 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">rs7903146</th>
###xml 480 481 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 480 495 480 495 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value (ANOVA)</th>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 495 513 495 513 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value (CC vs XT)</th>
###xml 470 513 470 513 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr>
###xml 470 513 470 513 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead>
###xml 513 521 513 521 <td xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</td>
###xml 521 524 521 524 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/C</td>
###xml 524 527 524 527 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/T</td>
###xml 527 530 527 530 <td xmlns:xlink="http://www.w3.org/1999/xlink">T/T</td>
###xml 530 530 530 530 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 530 530 530 530 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 513 530 513 530 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr>
###xml 530 531 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 530 531 530 531 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></td>
###xml 531 534 531 534 <td xmlns:xlink="http://www.w3.org/1999/xlink">546</td>
###xml 534 537 534 537 <td xmlns:xlink="http://www.w3.org/1999/xlink">474</td>
###xml 537 539 537 539 <td xmlns:xlink="http://www.w3.org/1999/xlink">90</td>
###xml 539 539 539 539 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 539 539 539 539 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 530 539 530 539 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>n</italic></td><td>546</td><td>474</td><td>90</td><td/><td/></tr>
###xml 539 546 539 546 <td xmlns:xlink="http://www.w3.org/1999/xlink">NGT/IGT</td>
###xml 546 552 546 552 <td xmlns:xlink="http://www.w3.org/1999/xlink">461/85</td>
###xml 552 558 552 558 <td xmlns:xlink="http://www.w3.org/1999/xlink">386/88</td>
###xml 558 563 558 563 <td xmlns:xlink="http://www.w3.org/1999/xlink">63/27</td>
###xml 563 568 563 568 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.007</td>
###xml 568 572 568 572 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.03</td>
###xml 539 572 539 572 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>NGT/IGT</td><td>461/85</td><td>386/88</td><td>63/27</td><td>0.007</td><td>0.03</td></tr>
###xml 572 589 572 589 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex (female/male)</td>
###xml 589 596 589 596 <td xmlns:xlink="http://www.w3.org/1999/xlink">346/200</td>
###xml 596 603 596 603 <td xmlns:xlink="http://www.w3.org/1999/xlink">315/159</td>
###xml 603 608 603 608 <td xmlns:xlink="http://www.w3.org/1999/xlink">50/40</td>
###xml 608 612 608 612 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.13</td>
###xml 612 616 612 616 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.64</td>
###xml 572 616 572 616 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex (female/male)</td><td>346/200</td><td>315/159</td><td>50/40</td><td>0.13</td><td>0.64</td></tr>
###xml 616 627 616 627 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 627 635 627 633 <td xmlns:xlink="http://www.w3.org/1999/xlink">39&#8201;&#177;&#8201;1</td>
###xml 635 643 633 639 <td xmlns:xlink="http://www.w3.org/1999/xlink">40&#8201;&#177;&#8201;1</td>
###xml 643 651 639 645 <td xmlns:xlink="http://www.w3.org/1999/xlink">41&#8201;&#177;&#8201;1</td>
###xml 651 655 645 649 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.39</td>
###xml 655 659 649 653 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.67</td>
###xml 616 659 616 653 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>39&#8201;&#177;&#8201;1</td><td>40&#8201;&#177;&#8201;1</td><td>41&#8201;&#177;&#8201;1</td><td>0.39</td><td>0.67</td></tr>
###xml 668 669 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 659 670 653 664 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 670 682 664 674 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.5&#8201;&#177;&#8201;0.4</td>
###xml 682 694 674 684 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.9&#8201;&#177;&#8201;0.4</td>
###xml 694 706 684 694 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.2&#8201;&#177;&#8201;1.0</td>
###xml 706 710 694 698 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.51</td>
###xml 710 714 698 702 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.24</td>
###xml 659 714 653 702 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td>29.5&#8201;&#177;&#8201;0.4</td><td>28.9&#8201;&#177;&#8201;0.4</td><td>28.2&#8201;&#177;&#8201;1.0</td><td>0.51</td><td>0.24</td></tr>
###xml 714 737 702 725 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Plasma glucose (mmol/l)</td>
###xml 714 737 702 725 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Plasma glucose (mmol/l)</td></tr>
###xml 737 746 725 734 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Fasting </td>
###xml 746 758 734 744 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#8201;&#177;&#8201;0.02</td>
###xml 758 770 744 754 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#8201;&#177;&#8201;0.02</td>
###xml 770 782 754 764 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.2&#8201;&#177;&#8201;0.07</td>
###xml 782 786 764 768 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.25</td>
###xml 786 790 768 772 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.39</td>
###xml 737 790 725 772 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Fasting </td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.2&#8201;&#177;&#8201;0.07</td><td>0.25</td><td>0.39</td></tr>
###xml 790 795 772 777 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;2&#160;h </td>
###xml 795 807 777 787 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.1&#8201;&#177;&#8201;0.07</td>
###xml 807 819 787 797 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.2&#8201;&#177;&#8201;0.07</td>
###xml 819 830 797 806 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.7&#8201;&#177;&#8201;0.2</td>
###xml 830 834 806 810 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.06</td>
###xml 834 838 810 814 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.17</td>
###xml 790 838 772 814 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;2&#160;h </td><td>6.1&#8201;&#177;&#8201;0.07</td><td>6.2&#8201;&#177;&#8201;0.07</td><td>6.7&#8201;&#177;&#8201;0.2</td><td>0.06</td><td>0.17</td></tr>
###xml 838 861 814 837 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Plasma insulin (pmol/l)</td>
###xml 838 861 814 837 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Plasma insulin (pmol/l)</td></tr>
###xml 861 869 837 845 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Fasting</td>
###xml 869 881 845 855 <td xmlns:xlink="http://www.w3.org/1999/xlink">62.0&#8201;&#177;&#8201;2.1</td>
###xml 881 893 855 865 <td xmlns:xlink="http://www.w3.org/1999/xlink">53.4&#8201;&#177;&#8201;1.7</td>
###xml 893 905 865 875 <td xmlns:xlink="http://www.w3.org/1999/xlink">49.8&#8201;&#177;&#8201;3.1</td>
###xml 905 910 875 880 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.004</td>
###xml 910 915 880 885 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.001</td>
###xml 861 915 837 885 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Fasting</td><td>62.0&#8201;&#177;&#8201;2.1</td><td>53.4&#8201;&#177;&#8201;1.7</td><td>49.8&#8201;&#177;&#8201;3.1</td><td>0.004</td><td>0.001</td></tr>
###xml 915 919 885 889 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;2&#160;h</td>
###xml 919 929 889 897 <td xmlns:xlink="http://www.w3.org/1999/xlink">442&#8201;&#177;&#8201;19</td>
###xml 929 939 897 905 <td xmlns:xlink="http://www.w3.org/1999/xlink">356&#8201;&#177;&#8201;17</td>
###xml 939 949 905 913 <td xmlns:xlink="http://www.w3.org/1999/xlink">372&#8201;&#177;&#8201;34</td>
###xml 949 953 913 917 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.12</td>
###xml 953 957 917 921 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.04</td>
###xml 915 957 885 921 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;2&#160;h</td><td>442&#8201;&#177;&#8201;19</td><td>356&#8201;&#177;&#8201;17</td><td>372&#8201;&#177;&#8201;34</td><td>0.12</td><td>0.04</td></tr>
###xml 976 980 940 944 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OGTT</sub>
###xml 957 998 921 962 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin sensitivity<sub>OGTT</sub> (arbitrary units)</td>
###xml 998 1010 962 972 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.8&#8201;&#177;&#8201;0.5</td>
###xml 1010 1022 972 982 <td xmlns:xlink="http://www.w3.org/1999/xlink">18.2&#8201;&#177;&#8201;0.5</td>
###xml 1022 1034 982 992 <td xmlns:xlink="http://www.w3.org/1999/xlink">17.8&#8201;&#177;&#8201;1.2</td>
###xml 1043 1044 1001 1002 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1034 1044 992 1002 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.02/0.02<sup>a</sup></td>
###xml 1055 1056 1013 1014 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1044 1056 1002 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.005/0.006<sup>a</sup></td>
###xml 957 1056 921 1014 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units)</td><td>16.8&#8201;&#177;&#8201;0.5</td><td>18.2&#8201;&#177;&#8201;0.5</td><td>17.8&#8201;&#177;&#8201;1.2</td><td>0.02/0.02<sup>a</sup></td><td>0.005/0.006<sup>a</sup></td></tr>
###xml 1073 1077 1031 1035 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OGTT</sub>
###xml 1056 1089 1014 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td>
###xml 1089 1098 1047 1054 <td xmlns:xlink="http://www.w3.org/1999/xlink">319&#8201;&#177;&#8201;5</td>
###xml 1098 1107 1054 1061 <td xmlns:xlink="http://www.w3.org/1999/xlink">301&#8201;&#177;&#8201;5</td>
###xml 1107 1117 1061 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink">292&#8201;&#177;&#8201;10</td>
###xml 1127 1128 1079 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1117 1128 1069 1080 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.003/0.04<sup>b</sup></td>
###xml 1139 1140 1091 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1128 1140 1080 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0009/0.02<sup>b</sup></td>
###xml 1056 1140 1014 1092 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>319&#8201;&#177;&#8201;5</td><td>301&#8201;&#177;&#8201;5</td><td>292&#8201;&#177;&#8201;10</td><td>0.003/0.04<sup>b</sup></td><td>0.0009/0.02<sup>b</sup></td></tr>
###xml 1140 1173 1092 1125 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin/glucose ratio (pmol/mmol)</td>
###xml 1173 1182 1125 1132 <td xmlns:xlink="http://www.w3.org/1999/xlink">143&#8201;&#177;&#8201;5</td>
###xml 1182 1191 1132 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink">127&#8201;&#177;&#8201;5</td>
###xml 1191 1201 1139 1147 <td xmlns:xlink="http://www.w3.org/1999/xlink">124&#8201;&#177;&#8201;13</td>
###xml 1211 1212 1157 1158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1201 1212 1147 1158 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.003/0.03<sup>b</sup></td>
###xml 1222 1223 1168 1169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1212 1223 1158 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.001/0.01<sup>b</sup></td>
###xml 1140 1223 1092 1169 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin/glucose ratio (pmol/mmol)</td><td>143&#8201;&#177;&#8201;5</td><td>127&#8201;&#177;&#8201;5</td><td>124&#8201;&#177;&#8201;13</td><td>0.003/0.03<sup>b</sup></td><td>0.001/0.01<sup>b</sup></td></tr>
###xml 513 1223 513 1169 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr><tr><td><italic>n</italic></td><td>546</td><td>474</td><td>90</td><td/><td/></tr><tr><td>NGT/IGT</td><td>461/85</td><td>386/88</td><td>63/27</td><td>0.007</td><td>0.03</td></tr><tr><td>Sex (female/male)</td><td>346/200</td><td>315/159</td><td>50/40</td><td>0.13</td><td>0.64</td></tr><tr><td>Age (years)</td><td>39&#8201;&#177;&#8201;1</td><td>40&#8201;&#177;&#8201;1</td><td>41&#8201;&#177;&#8201;1</td><td>0.39</td><td>0.67</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.5&#8201;&#177;&#8201;0.4</td><td>28.9&#8201;&#177;&#8201;0.4</td><td>28.2&#8201;&#177;&#8201;1.0</td><td>0.51</td><td>0.24</td></tr><tr><td colspan="6">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting </td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.2&#8201;&#177;&#8201;0.07</td><td>0.25</td><td>0.39</td></tr><tr><td>&#160;2&#160;h </td><td>6.1&#8201;&#177;&#8201;0.07</td><td>6.2&#8201;&#177;&#8201;0.07</td><td>6.7&#8201;&#177;&#8201;0.2</td><td>0.06</td><td>0.17</td></tr><tr><td colspan="6">Plasma insulin (pmol/l)</td></tr><tr><td>&#160;Fasting</td><td>62.0&#8201;&#177;&#8201;2.1</td><td>53.4&#8201;&#177;&#8201;1.7</td><td>49.8&#8201;&#177;&#8201;3.1</td><td>0.004</td><td>0.001</td></tr><tr><td>&#160;2&#160;h</td><td>442&#8201;&#177;&#8201;19</td><td>356&#8201;&#177;&#8201;17</td><td>372&#8201;&#177;&#8201;34</td><td>0.12</td><td>0.04</td></tr><tr><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units)</td><td>16.8&#8201;&#177;&#8201;0.5</td><td>18.2&#8201;&#177;&#8201;0.5</td><td>17.8&#8201;&#177;&#8201;1.2</td><td>0.02/0.02<sup>a</sup></td><td>0.005/0.006<sup>a</sup></td></tr><tr><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>319&#8201;&#177;&#8201;5</td><td>301&#8201;&#177;&#8201;5</td><td>292&#8201;&#177;&#8201;10</td><td>0.003/0.04<sup>b</sup></td><td>0.0009/0.02<sup>b</sup></td></tr><tr><td>Insulin/glucose ratio (pmol/mmol)</td><td>143&#8201;&#177;&#8201;5</td><td>127&#8201;&#177;&#8201;5</td><td>124&#8201;&#177;&#8201;13</td><td>0.003/0.03<sup>b</sup></td><td>0.001/0.01<sup>b</sup></td></tr></tbody>
###xml 470 1223 470 1169 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr><tr><td><italic>n</italic></td><td>546</td><td>474</td><td>90</td><td/><td/></tr><tr><td>NGT/IGT</td><td>461/85</td><td>386/88</td><td>63/27</td><td>0.007</td><td>0.03</td></tr><tr><td>Sex (female/male)</td><td>346/200</td><td>315/159</td><td>50/40</td><td>0.13</td><td>0.64</td></tr><tr><td>Age (years)</td><td>39&#8201;&#177;&#8201;1</td><td>40&#8201;&#177;&#8201;1</td><td>41&#8201;&#177;&#8201;1</td><td>0.39</td><td>0.67</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.5&#8201;&#177;&#8201;0.4</td><td>28.9&#8201;&#177;&#8201;0.4</td><td>28.2&#8201;&#177;&#8201;1.0</td><td>0.51</td><td>0.24</td></tr><tr><td colspan="6">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting </td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.2&#8201;&#177;&#8201;0.07</td><td>0.25</td><td>0.39</td></tr><tr><td>&#160;2&#160;h </td><td>6.1&#8201;&#177;&#8201;0.07</td><td>6.2&#8201;&#177;&#8201;0.07</td><td>6.7&#8201;&#177;&#8201;0.2</td><td>0.06</td><td>0.17</td></tr><tr><td colspan="6">Plasma insulin (pmol/l)</td></tr><tr><td>&#160;Fasting</td><td>62.0&#8201;&#177;&#8201;2.1</td><td>53.4&#8201;&#177;&#8201;1.7</td><td>49.8&#8201;&#177;&#8201;3.1</td><td>0.004</td><td>0.001</td></tr><tr><td>&#160;2&#160;h</td><td>442&#8201;&#177;&#8201;19</td><td>356&#8201;&#177;&#8201;17</td><td>372&#8201;&#177;&#8201;34</td><td>0.12</td><td>0.04</td></tr><tr><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units)</td><td>16.8&#8201;&#177;&#8201;0.5</td><td>18.2&#8201;&#177;&#8201;0.5</td><td>17.8&#8201;&#177;&#8201;1.2</td><td>0.02/0.02<sup>a</sup></td><td>0.005/0.006<sup>a</sup></td></tr><tr><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>319&#8201;&#177;&#8201;5</td><td>301&#8201;&#177;&#8201;5</td><td>292&#8201;&#177;&#8201;10</td><td>0.003/0.04<sup>b</sup></td><td>0.0009/0.02<sup>b</sup></td></tr><tr><td>Insulin/glucose ratio (pmol/mmol)</td><td>143&#8201;&#177;&#8201;5</td><td>127&#8201;&#177;&#8201;5</td><td>124&#8201;&#177;&#8201;13</td><td>0.003/0.03<sup>b</sup></td><td>0.001/0.01<sup>b</sup></td></tr></tbody></table>
###xml 1223 1245 1169 1189 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">Data are means&#8201;&#177;&#8201;SEM</p>
###xml 1245 1246 1189 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1274 1277 1218 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 1277 1278 1219 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1245 1292 1189 1234 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or ANOVA</p>
###xml 1391 1392 1333 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1405 1406 1347 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1516 1517 1458 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1292 1534 1234 1476 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21">Analysis for rs12255372 and rs7901695 also revealed a significant difference in insulin secretion (<italic>p</italic>&#8201;=&#8201;0.003 and <italic>p</italic>&#8201;=&#8201;0.05), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (<italic>p</italic>&#8201;=&#8201;0.53 and 0.45)</p>
###xml 1534 1535 1476 1477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1535 1536 1477 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1534 1629 1476 1571 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22"><sup>a</sup><italic>p</italic> values are derived from multivariate linear regression models: adjusted for age, sex and BMI</p>
###xml 1629 1630 1571 1572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1630 1631 1572 1573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1629 1745 1571 1687 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23"><sup>b</sup><italic>p</italic> values are derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity</p>
###xml 1223 1745 1169 1687 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="19">Data are means&#8201;&#177;&#8201;SEM</p><p textid="20"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or ANOVA</p><p textid="21">Analysis for rs12255372 and rs7901695 also revealed a significant difference in insulin secretion (<italic>p</italic>&#8201;=&#8201;0.003 and <italic>p</italic>&#8201;=&#8201;0.05), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (<italic>p</italic>&#8201;=&#8201;0.53 and 0.45)</p><p textid="22"><sup>a</sup><italic>p</italic> values are derived from multivariate linear regression models: adjusted for age, sex and BMI</p><p textid="23"><sup>b</sup><italic>p</italic> values are derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity</p></table-wrap-foot>
###xml 380 1745 380 1687 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="18">Anthropometric and metabolic data from all 1,110 participants who underwent an OGTT</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr><tr><td><italic>n</italic></td><td>546</td><td>474</td><td>90</td><td/><td/></tr><tr><td>NGT/IGT</td><td>461/85</td><td>386/88</td><td>63/27</td><td>0.007</td><td>0.03</td></tr><tr><td>Sex (female/male)</td><td>346/200</td><td>315/159</td><td>50/40</td><td>0.13</td><td>0.64</td></tr><tr><td>Age (years)</td><td>39&#8201;&#177;&#8201;1</td><td>40&#8201;&#177;&#8201;1</td><td>41&#8201;&#177;&#8201;1</td><td>0.39</td><td>0.67</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.5&#8201;&#177;&#8201;0.4</td><td>28.9&#8201;&#177;&#8201;0.4</td><td>28.2&#8201;&#177;&#8201;1.0</td><td>0.51</td><td>0.24</td></tr><tr><td colspan="6">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting </td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.1&#8201;&#177;&#8201;0.02</td><td>5.2&#8201;&#177;&#8201;0.07</td><td>0.25</td><td>0.39</td></tr><tr><td>&#160;2&#160;h </td><td>6.1&#8201;&#177;&#8201;0.07</td><td>6.2&#8201;&#177;&#8201;0.07</td><td>6.7&#8201;&#177;&#8201;0.2</td><td>0.06</td><td>0.17</td></tr><tr><td colspan="6">Plasma insulin (pmol/l)</td></tr><tr><td>&#160;Fasting</td><td>62.0&#8201;&#177;&#8201;2.1</td><td>53.4&#8201;&#177;&#8201;1.7</td><td>49.8&#8201;&#177;&#8201;3.1</td><td>0.004</td><td>0.001</td></tr><tr><td>&#160;2&#160;h</td><td>442&#8201;&#177;&#8201;19</td><td>356&#8201;&#177;&#8201;17</td><td>372&#8201;&#177;&#8201;34</td><td>0.12</td><td>0.04</td></tr><tr><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units)</td><td>16.8&#8201;&#177;&#8201;0.5</td><td>18.2&#8201;&#177;&#8201;0.5</td><td>17.8&#8201;&#177;&#8201;1.2</td><td>0.02/0.02<sup>a</sup></td><td>0.005/0.006<sup>a</sup></td></tr><tr><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>319&#8201;&#177;&#8201;5</td><td>301&#8201;&#177;&#8201;5</td><td>292&#8201;&#177;&#8201;10</td><td>0.003/0.04<sup>b</sup></td><td>0.0009/0.02<sup>b</sup></td></tr><tr><td>Insulin/glucose ratio (pmol/mmol)</td><td>143&#8201;&#177;&#8201;5</td><td>127&#8201;&#177;&#8201;5</td><td>124&#8201;&#177;&#8201;13</td><td>0.003/0.03<sup>b</sup></td><td>0.001/0.01<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p textid="19">Data are means&#8201;&#177;&#8201;SEM</p><p textid="20"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or ANOVA</p><p textid="21">Analysis for rs12255372 and rs7901695 also revealed a significant difference in insulin secretion (<italic>p</italic>&#8201;=&#8201;0.003 and <italic>p</italic>&#8201;=&#8201;0.05), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (<italic>p</italic>&#8201;=&#8201;0.53 and 0.45)</p><p textid="22"><sup>a</sup><italic>p</italic> values are derived from multivariate linear regression models: adjusted for age, sex and BMI</p><p textid="23"><sup>b</sup><italic>p</italic> values are derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity</p></table-wrap-foot></table-wrap>
###xml 1745 1752 1687 1694 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1752 1859 1694 1801 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Anthropometric and metabolic data of the subgroup of 155 participants with additional measurements of GLP-1</p>
###xml 1752 1859 1694 1801 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Anthropometric and metabolic data of the subgroup of 155 participants with additional measurements of GLP-1</p></caption>
###xml 1859 1860 1801 1802 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</th>
###xml 1860 1869 1802 1811 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">rs7903146</th>
###xml 1869 1870 1811 1812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1869 1884 1811 1826 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value (ANOVA)</th>
###xml 1884 1885 1826 1827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1884 1902 1826 1844 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value (CC vs XT)</th>
###xml 1859 1902 1801 1844 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr>
###xml 1859 1902 1801 1844 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead>
###xml 1902 1910 1844 1852 <td xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</td>
###xml 1910 1913 1852 1855 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/C</td>
###xml 1913 1916 1855 1858 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/T</td>
###xml 1916 1919 1858 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink">T/T</td>
###xml 1919 1919 1861 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1919 1919 1861 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1902 1919 1844 1861 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr>
###xml 1919 1920 1861 1862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1919 1920 1861 1862 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></td>
###xml 1920 1922 1862 1864 <td xmlns:xlink="http://www.w3.org/1999/xlink">73</td>
###xml 1922 1924 1864 1866 <td xmlns:xlink="http://www.w3.org/1999/xlink">67</td>
###xml 1924 1926 1866 1868 <td xmlns:xlink="http://www.w3.org/1999/xlink">15</td>
###xml 1926 1926 1868 1868 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1926 1926 1868 1868 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1919 1926 1861 1868 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>n</italic></td><td>73</td><td>67</td><td>15</td><td/><td/></tr>
###xml 1926 1933 1868 1875 <td xmlns:xlink="http://www.w3.org/1999/xlink">NGT/IGT</td>
###xml 1933 1937 1875 1879 <td xmlns:xlink="http://www.w3.org/1999/xlink">64/9</td>
###xml 1937 1942 1879 1884 <td xmlns:xlink="http://www.w3.org/1999/xlink">48/19</td>
###xml 1942 1946 1884 1888 <td xmlns:xlink="http://www.w3.org/1999/xlink">10/5</td>
###xml 1946 1950 1888 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.03</td>
###xml 1950 1955 1892 1897 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.009</td>
###xml 1926 1955 1868 1897 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>NGT/IGT</td><td>64/9</td><td>48/19</td><td>10/5</td><td>0.03</td><td>0.009</td></tr>
###xml 1955 1972 1897 1914 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex (female/male)</td>
###xml 1972 1977 1914 1919 <td xmlns:xlink="http://www.w3.org/1999/xlink">50/23</td>
###xml 1977 1982 1919 1924 <td xmlns:xlink="http://www.w3.org/1999/xlink">42/25</td>
###xml 1982 1985 1924 1927 <td xmlns:xlink="http://www.w3.org/1999/xlink">8/7</td>
###xml 1985 1989 1927 1931 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.50</td>
###xml 1989 1993 1931 1935 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.33</td>
###xml 1955 1993 1897 1935 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex (female/male)</td><td>50/23</td><td>42/25</td><td>8/7</td><td>0.50</td><td>0.33</td></tr>
###xml 1993 2004 1935 1946 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 2004 2012 1946 1952 <td xmlns:xlink="http://www.w3.org/1999/xlink">46&#8201;&#177;&#8201;1</td>
###xml 2012 2020 1952 1958 <td xmlns:xlink="http://www.w3.org/1999/xlink">47&#8201;&#177;&#8201;1</td>
###xml 2020 2028 1958 1964 <td xmlns:xlink="http://www.w3.org/1999/xlink">47&#8201;&#177;&#8201;3</td>
###xml 2028 2032 1964 1968 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.99</td>
###xml 2032 2036 1968 1972 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.96</td>
###xml 1993 2036 1935 1972 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>46&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;3</td><td>0.99</td><td>0.96</td></tr>
###xml 2045 2046 1981 1982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2036 2047 1972 1983 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 2047 2059 1983 1993 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.8&#8201;&#177;&#8201;0.7</td>
###xml 2059 2071 1993 2003 <td xmlns:xlink="http://www.w3.org/1999/xlink">30.3&#8201;&#177;&#8201;0.7</td>
###xml 2071 2083 2003 2013 <td xmlns:xlink="http://www.w3.org/1999/xlink">27.1&#8201;&#177;&#8201;1.1</td>
###xml 2083 2087 2013 2017 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.15</td>
###xml 2087 2091 2017 2021 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.88</td>
###xml 2036 2091 1972 2021 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td>29.8&#8201;&#177;&#8201;0.7</td><td>30.3&#8201;&#177;&#8201;0.7</td><td>27.1&#8201;&#177;&#8201;1.1</td><td>0.15</td><td>0.88</td></tr>
###xml 2091 2114 2021 2044 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Plasma glucose (mmol/l)</td>
###xml 2091 2114 2021 2044 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Plasma glucose (mmol/l)</td></tr>
###xml 2114 2122 2044 2052 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Fasting</td>
###xml 2122 2134 2052 2062 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.2&#8201;&#177;&#8201;0.05</td>
###xml 2134 2146 2062 2072 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.3&#8201;&#177;&#8201;0.07</td>
###xml 2146 2157 2072 2081 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.6&#8201;&#177;&#8201;0.2</td>
###xml 2157 2161 2081 2085 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.17</td>
###xml 2161 2165 2085 2089 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.21</td>
###xml 2114 2165 2044 2089 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Fasting</td><td>5.2&#8201;&#177;&#8201;0.05</td><td>5.3&#8201;&#177;&#8201;0.07</td><td>5.6&#8201;&#177;&#8201;0.2</td><td>0.17</td><td>0.21</td></tr>
###xml 2165 2169 2089 2093 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;2&#160;h</td>
###xml 2169 2180 2093 2102 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.5&#8201;&#177;&#8201;0.1</td>
###xml 2180 2191 2102 2111 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.0&#8201;&#177;&#8201;0.2</td>
###xml 2191 2202 2111 2120 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.2&#8201;&#177;&#8201;0.5</td>
###xml 2202 2206 2120 2124 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.22</td>
###xml 2206 2210 2124 2128 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.10</td>
###xml 2165 2210 2089 2128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;2&#160;h</td><td>6.5&#8201;&#177;&#8201;0.1</td><td>7.0&#8201;&#177;&#8201;0.2</td><td>7.2&#8201;&#177;&#8201;0.5</td><td>0.22</td><td>0.10</td></tr>
###xml 2229 2233 2147 2151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OGTT</sub>
###xml 2210 2252 2128 2170 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin sensitivity<sub>OGTT</sub> (arbitrary units) </td>
###xml 2252 2264 2170 2180 <td xmlns:xlink="http://www.w3.org/1999/xlink">12.8&#8201;&#177;&#8201;0.7</td>
###xml 2264 2276 2180 2190 <td xmlns:xlink="http://www.w3.org/1999/xlink">13.6&#8201;&#177;&#8201;1.0</td>
###xml 2276 2288 2190 2200 <td xmlns:xlink="http://www.w3.org/1999/xlink">15.7&#8201;&#177;&#8201;2.6</td>
###xml 2297 2298 2209 2210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2288 2298 2200 2210 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.74/0.92<sup>a</sup></td>
###xml 2307 2308 2219 2220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2298 2308 2210 2220 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.78/0.75<sup>a</sup></td>
###xml 2210 2308 2128 2220 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units) </td><td>12.8&#8201;&#177;&#8201;0.7</td><td>13.6&#8201;&#177;&#8201;1.0</td><td>15.7&#8201;&#177;&#8201;2.6</td><td>0.74/0.92<sup>a</sup></td><td>0.78/0.75<sup>a</sup></td></tr>
###xml 2325 2329 2237 2241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OGTT</sub>
###xml 2308 2341 2220 2253 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td>
###xml 2341 2351 2253 2261 <td xmlns:xlink="http://www.w3.org/1999/xlink">304&#8201;&#177;&#8201;12</td>
###xml 2351 2361 2261 2269 <td xmlns:xlink="http://www.w3.org/1999/xlink">287&#8201;&#177;&#8201;13</td>
###xml 2361 2371 2269 2277 <td xmlns:xlink="http://www.w3.org/1999/xlink">235&#8201;&#177;&#8201;19</td>
###xml 2380 2381 2286 2287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2371 2381 2277 2287 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.01/0.02<sup>b</sup></td>
###xml 2390 2391 2296 2297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2381 2391 2287 2297 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.02/0.01<sup>b</sup></td>
###xml 2308 2391 2220 2297 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>304&#8201;&#177;&#8201;12</td><td>287&#8201;&#177;&#8201;13</td><td>235&#8201;&#177;&#8201;19</td><td>0.01/0.02<sup>b</sup></td><td>0.02/0.01<sup>b</sup></td></tr>
###xml 2391 2405 2297 2311 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">GLP-1 (pmol/l)</td>
###xml 2391 2405 2297 2311 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">GLP-1 (pmol/l)</td></tr>
###xml 2405 2412 2311 2318 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;0&#160;min </td>
###xml 2412 2424 2318 2328 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.1&#8201;&#177;&#8201;0.9</td>
###xml 2424 2436 2328 2338 <td xmlns:xlink="http://www.w3.org/1999/xlink">17.3&#8201;&#177;&#8201;1.3</td>
###xml 2436 2448 2338 2348 <td xmlns:xlink="http://www.w3.org/1999/xlink">17.3&#8201;&#177;&#8201;2.0</td>
###xml 2448 2452 2348 2352 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.91</td>
###xml 2452 2456 2352 2356 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.88</td>
###xml 2405 2456 2311 2356 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;0&#160;min </td><td>16.1&#8201;&#177;&#8201;0.9</td><td>17.3&#8201;&#177;&#8201;1.3</td><td>17.3&#8201;&#177;&#8201;2.0</td><td>0.91</td><td>0.88</td></tr>
###xml 2456 2463 2356 2363 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;30&#160;min</td>
###xml 2463 2475 2363 2373 <td xmlns:xlink="http://www.w3.org/1999/xlink">34.1&#8201;&#177;&#8201;2.1</td>
###xml 2475 2487 2373 2383 <td xmlns:xlink="http://www.w3.org/1999/xlink">38.8&#8201;&#177;&#8201;4.0</td>
###xml 2487 2499 2383 2393 <td xmlns:xlink="http://www.w3.org/1999/xlink">38.1&#8201;&#177;&#8201;3.5</td>
###xml 2499 2503 2393 2397 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.45</td>
###xml 2503 2507 2397 2401 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.36</td>
###xml 2456 2507 2356 2401 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;30&#160;min</td><td>34.1&#8201;&#177;&#8201;2.1</td><td>38.8&#8201;&#177;&#8201;4.0</td><td>38.1&#8201;&#177;&#8201;3.5</td><td>0.45</td><td>0.36</td></tr>
###xml 2507 2515 2401 2409 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;120&#160;min</td>
###xml 2515 2527 2409 2419 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.9&#8201;&#177;&#8201;1.5</td>
###xml 2527 2539 2419 2429 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.0&#8201;&#177;&#8201;1.7</td>
###xml 2539 2551 2429 2439 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.9&#8201;&#177;&#8201;2.4</td>
###xml 2551 2555 2439 2443 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.87</td>
###xml 2555 2559 2443 2447 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.88</td>
###xml 2507 2559 2401 2447 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;120&#160;min</td><td>28.9&#8201;&#177;&#8201;1.5</td><td>29.0&#8201;&#177;&#8201;1.7</td><td>28.9&#8201;&#177;&#8201;2.4</td><td>0.87</td><td>0.88</td></tr>
###xml 2559 2582 2447 2470 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Fold increase 0&#8211;30&#160;min</td>
###xml 2582 2593 2470 2479 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.5&#8201;&#177;&#8201;0.2</td>
###xml 2593 2604 2479 2488 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.7&#8201;&#177;&#8201;0.3</td>
###xml 2604 2615 2488 2497 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.4&#8201;&#177;&#8201;0.4</td>
###xml 2615 2619 2497 2501 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.77</td>
###xml 2619 2623 2501 2505 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.84</td>
###xml 2559 2623 2447 2505 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Fold increase 0&#8211;30&#160;min</td><td>2.5&#8201;&#177;&#8201;0.2</td><td>2.7&#8201;&#177;&#8201;0.3</td><td>2.4&#8201;&#177;&#8201;0.4</td><td>0.77</td><td>0.84</td></tr>
###xml 1902 2623 1844 2505 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr><tr><td><italic>n</italic></td><td>73</td><td>67</td><td>15</td><td/><td/></tr><tr><td>NGT/IGT</td><td>64/9</td><td>48/19</td><td>10/5</td><td>0.03</td><td>0.009</td></tr><tr><td>Sex (female/male)</td><td>50/23</td><td>42/25</td><td>8/7</td><td>0.50</td><td>0.33</td></tr><tr><td>Age (years)</td><td>46&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;3</td><td>0.99</td><td>0.96</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.8&#8201;&#177;&#8201;0.7</td><td>30.3&#8201;&#177;&#8201;0.7</td><td>27.1&#8201;&#177;&#8201;1.1</td><td>0.15</td><td>0.88</td></tr><tr><td colspan="6">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting</td><td>5.2&#8201;&#177;&#8201;0.05</td><td>5.3&#8201;&#177;&#8201;0.07</td><td>5.6&#8201;&#177;&#8201;0.2</td><td>0.17</td><td>0.21</td></tr><tr><td>&#160;2&#160;h</td><td>6.5&#8201;&#177;&#8201;0.1</td><td>7.0&#8201;&#177;&#8201;0.2</td><td>7.2&#8201;&#177;&#8201;0.5</td><td>0.22</td><td>0.10</td></tr><tr><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units) </td><td>12.8&#8201;&#177;&#8201;0.7</td><td>13.6&#8201;&#177;&#8201;1.0</td><td>15.7&#8201;&#177;&#8201;2.6</td><td>0.74/0.92<sup>a</sup></td><td>0.78/0.75<sup>a</sup></td></tr><tr><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>304&#8201;&#177;&#8201;12</td><td>287&#8201;&#177;&#8201;13</td><td>235&#8201;&#177;&#8201;19</td><td>0.01/0.02<sup>b</sup></td><td>0.02/0.01<sup>b</sup></td></tr><tr><td colspan="6">GLP-1 (pmol/l)</td></tr><tr><td>&#160;0&#160;min </td><td>16.1&#8201;&#177;&#8201;0.9</td><td>17.3&#8201;&#177;&#8201;1.3</td><td>17.3&#8201;&#177;&#8201;2.0</td><td>0.91</td><td>0.88</td></tr><tr><td>&#160;30&#160;min</td><td>34.1&#8201;&#177;&#8201;2.1</td><td>38.8&#8201;&#177;&#8201;4.0</td><td>38.1&#8201;&#177;&#8201;3.5</td><td>0.45</td><td>0.36</td></tr><tr><td>&#160;120&#160;min</td><td>28.9&#8201;&#177;&#8201;1.5</td><td>29.0&#8201;&#177;&#8201;1.7</td><td>28.9&#8201;&#177;&#8201;2.4</td><td>0.87</td><td>0.88</td></tr><tr><td>&#160;Fold increase 0&#8211;30&#160;min</td><td>2.5&#8201;&#177;&#8201;0.2</td><td>2.7&#8201;&#177;&#8201;0.3</td><td>2.4&#8201;&#177;&#8201;0.4</td><td>0.77</td><td>0.84</td></tr></tbody>
###xml 1859 2623 1801 2505 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr><tr><td><italic>n</italic></td><td>73</td><td>67</td><td>15</td><td/><td/></tr><tr><td>NGT/IGT</td><td>64/9</td><td>48/19</td><td>10/5</td><td>0.03</td><td>0.009</td></tr><tr><td>Sex (female/male)</td><td>50/23</td><td>42/25</td><td>8/7</td><td>0.50</td><td>0.33</td></tr><tr><td>Age (years)</td><td>46&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;3</td><td>0.99</td><td>0.96</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.8&#8201;&#177;&#8201;0.7</td><td>30.3&#8201;&#177;&#8201;0.7</td><td>27.1&#8201;&#177;&#8201;1.1</td><td>0.15</td><td>0.88</td></tr><tr><td colspan="6">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting</td><td>5.2&#8201;&#177;&#8201;0.05</td><td>5.3&#8201;&#177;&#8201;0.07</td><td>5.6&#8201;&#177;&#8201;0.2</td><td>0.17</td><td>0.21</td></tr><tr><td>&#160;2&#160;h</td><td>6.5&#8201;&#177;&#8201;0.1</td><td>7.0&#8201;&#177;&#8201;0.2</td><td>7.2&#8201;&#177;&#8201;0.5</td><td>0.22</td><td>0.10</td></tr><tr><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units) </td><td>12.8&#8201;&#177;&#8201;0.7</td><td>13.6&#8201;&#177;&#8201;1.0</td><td>15.7&#8201;&#177;&#8201;2.6</td><td>0.74/0.92<sup>a</sup></td><td>0.78/0.75<sup>a</sup></td></tr><tr><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>304&#8201;&#177;&#8201;12</td><td>287&#8201;&#177;&#8201;13</td><td>235&#8201;&#177;&#8201;19</td><td>0.01/0.02<sup>b</sup></td><td>0.02/0.01<sup>b</sup></td></tr><tr><td colspan="6">GLP-1 (pmol/l)</td></tr><tr><td>&#160;0&#160;min </td><td>16.1&#8201;&#177;&#8201;0.9</td><td>17.3&#8201;&#177;&#8201;1.3</td><td>17.3&#8201;&#177;&#8201;2.0</td><td>0.91</td><td>0.88</td></tr><tr><td>&#160;30&#160;min</td><td>34.1&#8201;&#177;&#8201;2.1</td><td>38.8&#8201;&#177;&#8201;4.0</td><td>38.1&#8201;&#177;&#8201;3.5</td><td>0.45</td><td>0.36</td></tr><tr><td>&#160;120&#160;min</td><td>28.9&#8201;&#177;&#8201;1.5</td><td>29.0&#8201;&#177;&#8201;1.7</td><td>28.9&#8201;&#177;&#8201;2.4</td><td>0.87</td><td>0.88</td></tr><tr><td>&#160;Fold increase 0&#8211;30&#160;min</td><td>2.5&#8201;&#177;&#8201;0.2</td><td>2.7&#8201;&#177;&#8201;0.3</td><td>2.4&#8201;&#177;&#8201;0.4</td><td>0.77</td><td>0.84</td></tr></tbody></table>
###xml 2623 2645 2505 2525 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25">Data are means&#8201;&#177;&#8201;SEM</p>
###xml 2645 2646 2525 2526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2674 2677 2554 2555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 2677 2678 2555 2556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2645 2692 2525 2570 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or ANOVA</p>
###xml 2776 2777 2654 2655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2887 2888 2765 2766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2692 2905 2570 2783 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Analysis for rs7901695 also revealed a significant difference in insulin secretion (<italic>p</italic>&#8201;=&#8201;0.02), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (<italic>p</italic>&#8201;=&#8201;0.73 and 0.76)</p>
###xml 2905 2906 2783 2784 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2906 2907 2784 2785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2905 3001 2783 2879 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><sup>a</sup><italic>p</italic> values were derived from multivariate linear regression models: adjusted for age, sex and BMI</p>
###xml 3001 3002 2879 2880 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 3002 3003 2880 2881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3001 3118 2879 2996 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><sup>b</sup><italic>p</italic> values were derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity</p>
###xml 2623 3118 2505 2996 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25">Data are means&#8201;&#177;&#8201;SEM</p><p textid="26"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or ANOVA</p><p textid="27">Analysis for rs7901695 also revealed a significant difference in insulin secretion (<italic>p</italic>&#8201;=&#8201;0.02), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (<italic>p</italic>&#8201;=&#8201;0.73 and 0.76)</p><p textid="28"><sup>a</sup><italic>p</italic> values were derived from multivariate linear regression models: adjusted for age, sex and BMI</p><p textid="29"><sup>b</sup><italic>p</italic> values were derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity</p></table-wrap-foot>
###xml 1745 3118 1687 2996 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="24">Anthropometric and metabolic data of the subgroup of 155 participants with additional measurements of GLP-1</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th colspan="3">rs7903146</th><th><italic>p</italic> value (ANOVA)</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>C/T</td><td>T/T</td><td/><td/></tr><tr><td><italic>n</italic></td><td>73</td><td>67</td><td>15</td><td/><td/></tr><tr><td>NGT/IGT</td><td>64/9</td><td>48/19</td><td>10/5</td><td>0.03</td><td>0.009</td></tr><tr><td>Sex (female/male)</td><td>50/23</td><td>42/25</td><td>8/7</td><td>0.50</td><td>0.33</td></tr><tr><td>Age (years)</td><td>46&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;3</td><td>0.99</td><td>0.96</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.8&#8201;&#177;&#8201;0.7</td><td>30.3&#8201;&#177;&#8201;0.7</td><td>27.1&#8201;&#177;&#8201;1.1</td><td>0.15</td><td>0.88</td></tr><tr><td colspan="6">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting</td><td>5.2&#8201;&#177;&#8201;0.05</td><td>5.3&#8201;&#177;&#8201;0.07</td><td>5.6&#8201;&#177;&#8201;0.2</td><td>0.17</td><td>0.21</td></tr><tr><td>&#160;2&#160;h</td><td>6.5&#8201;&#177;&#8201;0.1</td><td>7.0&#8201;&#177;&#8201;0.2</td><td>7.2&#8201;&#177;&#8201;0.5</td><td>0.22</td><td>0.10</td></tr><tr><td>Insulin sensitivity<sub>OGTT</sub> (arbitrary units) </td><td>12.8&#8201;&#177;&#8201;0.7</td><td>13.6&#8201;&#177;&#8201;1.0</td><td>15.7&#8201;&#177;&#8201;2.6</td><td>0.74/0.92<sup>a</sup></td><td>0.78/0.75<sup>a</sup></td></tr><tr><td>Insulin secretion<sub>OGTT</sub> (pmol/mmol)</td><td>304&#8201;&#177;&#8201;12</td><td>287&#8201;&#177;&#8201;13</td><td>235&#8201;&#177;&#8201;19</td><td>0.01/0.02<sup>b</sup></td><td>0.02/0.01<sup>b</sup></td></tr><tr><td colspan="6">GLP-1 (pmol/l)</td></tr><tr><td>&#160;0&#160;min </td><td>16.1&#8201;&#177;&#8201;0.9</td><td>17.3&#8201;&#177;&#8201;1.3</td><td>17.3&#8201;&#177;&#8201;2.0</td><td>0.91</td><td>0.88</td></tr><tr><td>&#160;30&#160;min</td><td>34.1&#8201;&#177;&#8201;2.1</td><td>38.8&#8201;&#177;&#8201;4.0</td><td>38.1&#8201;&#177;&#8201;3.5</td><td>0.45</td><td>0.36</td></tr><tr><td>&#160;120&#160;min</td><td>28.9&#8201;&#177;&#8201;1.5</td><td>29.0&#8201;&#177;&#8201;1.7</td><td>28.9&#8201;&#177;&#8201;2.4</td><td>0.87</td><td>0.88</td></tr><tr><td>&#160;Fold increase 0&#8211;30&#160;min</td><td>2.5&#8201;&#177;&#8201;0.2</td><td>2.7&#8201;&#177;&#8201;0.3</td><td>2.4&#8201;&#177;&#8201;0.4</td><td>0.77</td><td>0.84</td></tr></tbody></table><table-wrap-foot><p textid="25">Data are means&#8201;&#177;&#8201;SEM</p><p textid="26"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or ANOVA</p><p textid="27">Analysis for rs7901695 also revealed a significant difference in insulin secretion (<italic>p</italic>&#8201;=&#8201;0.02), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (<italic>p</italic>&#8201;=&#8201;0.73 and 0.76)</p><p textid="28"><sup>a</sup><italic>p</italic> values were derived from multivariate linear regression models: adjusted for age, sex and BMI</p><p textid="29"><sup>b</sup><italic>p</italic> values were derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity</p></table-wrap-foot></table-wrap>
###xml 3301 3303 3179 3181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 3312 3313 3190 3191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 3316 3323 3194 3201 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 3323 3447 3201 3325 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Anthropometric and metabolic data of 210 participants who underwent a combined IVGTT and hyperinsulinaemic&#8211;euglycaemic clamp</p>
###xml 3323 3447 3201 3325 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Anthropometric and metabolic data of 210 participants who underwent a combined IVGTT and hyperinsulinaemic&#8211;euglycaemic clamp</p></caption>
###xml 3447 3448 3325 3326 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</th>
###xml 3448 3457 3326 3335 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">rs7903146</th>
###xml 3457 3458 3335 3336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3457 3475 3335 3353 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value (CC vs XT)</th>
###xml 3447 3475 3325 3353 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#160;</th><th colspan="2">rs7903146</th><th><italic>p</italic> value (CC vs XT)</th></tr>
###xml 3447 3475 3325 3353 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>&#160;</th><th colspan="2">rs7903146</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead>
###xml 3475 3483 3353 3361 <td xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</td>
###xml 3483 3486 3361 3364 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/C</td>
###xml 3486 3489 3364 3367 <td xmlns:xlink="http://www.w3.org/1999/xlink">X/T</td>
###xml 3489 3489 3367 3367 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3475 3489 3353 3367 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Genotype</td><td>C/C</td><td>X/T</td><td/></tr>
###xml 3489 3490 3367 3368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 3489 3490 3367 3368 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></td>
###xml 3490 3492 3368 3370 <td xmlns:xlink="http://www.w3.org/1999/xlink">97</td>
###xml 3492 3495 3370 3373 <td xmlns:xlink="http://www.w3.org/1999/xlink">113</td>
###xml 3495 3495 3373 3373 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3489 3495 3367 3373 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>n</italic></td><td>97</td><td>113</td><td/></tr>
###xml 3495 3502 3373 3380 <td xmlns:xlink="http://www.w3.org/1999/xlink">NGT/IGT</td>
###xml 3502 3507 3380 3385 <td xmlns:xlink="http://www.w3.org/1999/xlink">80/17</td>
###xml 3507 3512 3385 3390 <td xmlns:xlink="http://www.w3.org/1999/xlink">81/32</td>
###xml 3512 3516 3390 3394 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.06</td>
###xml 3495 3516 3373 3394 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>NGT/IGT</td><td>80/17</td><td>81/32</td><td>0.06</td></tr>
###xml 3516 3533 3394 3411 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex (female/male)</td>
###xml 3533 3538 3411 3416 <td xmlns:xlink="http://www.w3.org/1999/xlink">59/38</td>
###xml 3538 3543 3416 3421 <td xmlns:xlink="http://www.w3.org/1999/xlink">64/49</td>
###xml 3543 3547 3421 3425 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.58</td>
###xml 3516 3547 3394 3425 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex (female/male)</td><td>59/38</td><td>64/49</td><td>0.58</td></tr>
###xml 3547 3558 3425 3436 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 3558 3566 3436 3442 <td xmlns:xlink="http://www.w3.org/1999/xlink">44&#8201;&#177;&#8201;1</td>
###xml 3566 3574 3442 3448 <td xmlns:xlink="http://www.w3.org/1999/xlink">45&#8201;&#177;&#8201;1</td>
###xml 3574 3578 3448 3452 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.29</td>
###xml 3547 3578 3425 3452 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>44&#8201;&#177;&#8201;1</td><td>45&#8201;&#177;&#8201;1</td><td>0.29</td></tr>
###xml 3587 3588 3461 3462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 3578 3589 3452 3463 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 3589 3601 3463 3473 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.0&#8201;&#177;&#8201;0.5</td>
###xml 3601 3613 3473 3483 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.8&#8201;&#177;&#8201;0.5</td>
###xml 3613 3617 3483 3487 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.82</td>
###xml 3578 3617 3452 3487 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td>29.0&#8201;&#177;&#8201;0.5</td><td>28.8&#8201;&#177;&#8201;0.5</td><td>0.82</td></tr>
###xml 3636 3641 3506 3511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">clamp</sub>
###xml 3651 3653 3520 3522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 3657 3659 3526 3528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 3668 3670 3537 3539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 3617 3671 3487 3540 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin sensitivity<sub>clamp</sub> (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td>
###xml 3671 3684 3540 3551 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.07&#8201;&#177;&#8201;0.01</td>
###xml 3684 3697 3551 3562 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.07&#8201;&#177;&#8201;0.01</td>
###xml 3697 3701 3562 3566 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.77</td>
###xml 3617 3701 3487 3566 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin sensitivity<sub>clamp</sub> (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.77</td></tr>
###xml 3724 3725 3589 3590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3701 3725 3566 3590 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin secretion index<sup>a</sup></td>
###xml 3725 3725 3590 3590 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3725 3725 3590 3590 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3725 3725 3590 3590 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3701 3725 3566 3590 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin secretion index<sup>a</sup></td><td/><td/><td/></tr>
###xml 3725 3760 3590 3625 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;IVGTT C-peptide secretion (pmol/l)</td>
###xml 3760 3773 3625 3636 <td xmlns:xlink="http://www.w3.org/1999/xlink">7,904&#8201;&#177;&#8201;306</td>
###xml 3773 3786 3636 3647 <td xmlns:xlink="http://www.w3.org/1999/xlink">7,679&#8201;&#177;&#8201;323</td>
###xml 3786 3790 3647 3651 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.40</td>
###xml 3725 3790 3590 3651 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;IVGTT C-peptide secretion (pmol/l)</td><td>7,904&#8201;&#177;&#8201;306</td><td>7,679&#8201;&#177;&#8201;323</td><td>0.40</td></tr>
###xml 3790 3823 3651 3684 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;IVGTT insulin secretion (pmol/l)</td>
###xml 3823 3836 3684 3695 <td xmlns:xlink="http://www.w3.org/1999/xlink">2,059&#8201;&#177;&#8201;131</td>
###xml 3836 3849 3695 3706 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,924&#8201;&#177;&#8201;129</td>
###xml 3849 3853 3706 3710 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.25</td>
###xml 3790 3853 3651 3710 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;IVGTT insulin secretion (pmol/l)</td><td>2,059&#8201;&#177;&#8201;131</td><td>1,924&#8201;&#177;&#8201;129</td><td>0.25</td></tr>
###xml 3853 3888 3710 3745 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;OGTT insulin secretion (pmol/mmol)</td>
###xml 3888 3897 3745 3752 <td xmlns:xlink="http://www.w3.org/1999/xlink">314&#8201;&#177;&#8201;8</td>
###xml 3897 3906 3752 3759 <td xmlns:xlink="http://www.w3.org/1999/xlink">292&#8201;&#177;&#8201;8</td>
###xml 3906 3910 3759 3763 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.04</td>
###xml 3853 3910 3710 3763 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;OGTT insulin secretion (pmol/mmol)</td><td>314&#8201;&#177;&#8201;8</td><td>292&#8201;&#177;&#8201;8</td><td>0.04</td></tr>
###xml 3475 3910 3353 3763 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Genotype</td><td>C/C</td><td>X/T</td><td/></tr><tr><td><italic>n</italic></td><td>97</td><td>113</td><td/></tr><tr><td>NGT/IGT</td><td>80/17</td><td>81/32</td><td>0.06</td></tr><tr><td>Sex (female/male)</td><td>59/38</td><td>64/49</td><td>0.58</td></tr><tr><td>Age (years)</td><td>44&#8201;&#177;&#8201;1</td><td>45&#8201;&#177;&#8201;1</td><td>0.29</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.0&#8201;&#177;&#8201;0.5</td><td>28.8&#8201;&#177;&#8201;0.5</td><td>0.82</td></tr><tr><td>Insulin sensitivity<sub>clamp</sub> (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.77</td></tr><tr><td>Insulin secretion index<sup>a</sup></td><td/><td/><td/></tr><tr><td>&#160;IVGTT C-peptide secretion (pmol/l)</td><td>7,904&#8201;&#177;&#8201;306</td><td>7,679&#8201;&#177;&#8201;323</td><td>0.40</td></tr><tr><td>&#160;IVGTT insulin secretion (pmol/l)</td><td>2,059&#8201;&#177;&#8201;131</td><td>1,924&#8201;&#177;&#8201;129</td><td>0.25</td></tr><tr><td>&#160;OGTT insulin secretion (pmol/mmol)</td><td>314&#8201;&#177;&#8201;8</td><td>292&#8201;&#177;&#8201;8</td><td>0.04</td></tr></tbody>
###xml 3447 3910 3325 3763 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th colspan="2">rs7903146</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>X/T</td><td/></tr><tr><td><italic>n</italic></td><td>97</td><td>113</td><td/></tr><tr><td>NGT/IGT</td><td>80/17</td><td>81/32</td><td>0.06</td></tr><tr><td>Sex (female/male)</td><td>59/38</td><td>64/49</td><td>0.58</td></tr><tr><td>Age (years)</td><td>44&#8201;&#177;&#8201;1</td><td>45&#8201;&#177;&#8201;1</td><td>0.29</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.0&#8201;&#177;&#8201;0.5</td><td>28.8&#8201;&#177;&#8201;0.5</td><td>0.82</td></tr><tr><td>Insulin sensitivity<sub>clamp</sub> (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.77</td></tr><tr><td>Insulin secretion index<sup>a</sup></td><td/><td/><td/></tr><tr><td>&#160;IVGTT C-peptide secretion (pmol/l)</td><td>7,904&#8201;&#177;&#8201;306</td><td>7,679&#8201;&#177;&#8201;323</td><td>0.40</td></tr><tr><td>&#160;IVGTT insulin secretion (pmol/l)</td><td>2,059&#8201;&#177;&#8201;131</td><td>1,924&#8201;&#177;&#8201;129</td><td>0.25</td></tr><tr><td>&#160;OGTT insulin secretion (pmol/mmol)</td><td>314&#8201;&#177;&#8201;8</td><td>292&#8201;&#177;&#8201;8</td><td>0.04</td></tr></tbody></table>
###xml 3910 3932 3763 3783 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Data are means&#8201;&#177;&#8201;SEM</p>
###xml 3932 3933 3783 3784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3961 3964 3812 3813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 3964 3965 3813 3814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 3983 3984 3832 3833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 3932 4030 3783 3879 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or unpaired <italic>t</italic> test or multivariate linear regression models</p>
###xml 4177 4178 4026 4027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 4030 4185 3879 4034 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">None of the four other SNPs in TCF7L2 (rs12255372, rs7901695, rs11196205 and rs7895340) affected significantly insulin secretion in the IVGTT (all <italic>p</italic>&#8201;&gt;&#8201;0.2)</p>
###xml 4185 4186 4034 4035 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4185 4240 4034 4089 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><sup>a</sup>Adjusted for age, sex and BMI, and insulin sensitivity</p>
###xml 3910 4240 3763 4089 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Data are means&#8201;&#177;&#8201;SEM</p><p textid="32"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or unpaired <italic>t</italic> test or multivariate linear regression models</p><p textid="33">None of the four other SNPs in TCF7L2 (rs12255372, rs7901695, rs11196205 and rs7895340) affected significantly insulin secretion in the IVGTT (all <italic>p</italic>&#8201;&gt;&#8201;0.2)</p><p textid="34"><sup>a</sup>Adjusted for age, sex and BMI, and insulin sensitivity</p></table-wrap-foot>
###xml 3316 4240 3194 4089 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="30">Anthropometric and metabolic data of 210 participants who underwent a combined IVGTT and hyperinsulinaemic&#8211;euglycaemic clamp</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th colspan="2">rs7903146</th><th><italic>p</italic> value (CC vs XT)</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>X/T</td><td/></tr><tr><td><italic>n</italic></td><td>97</td><td>113</td><td/></tr><tr><td>NGT/IGT</td><td>80/17</td><td>81/32</td><td>0.06</td></tr><tr><td>Sex (female/male)</td><td>59/38</td><td>64/49</td><td>0.58</td></tr><tr><td>Age (years)</td><td>44&#8201;&#177;&#8201;1</td><td>45&#8201;&#177;&#8201;1</td><td>0.29</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>29.0&#8201;&#177;&#8201;0.5</td><td>28.8&#8201;&#177;&#8201;0.5</td><td>0.82</td></tr><tr><td>Insulin sensitivity<sub>clamp</sub> (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.07&#8201;&#177;&#8201;0.01</td><td>0.77</td></tr><tr><td>Insulin secretion index<sup>a</sup></td><td/><td/><td/></tr><tr><td>&#160;IVGTT C-peptide secretion (pmol/l)</td><td>7,904&#8201;&#177;&#8201;306</td><td>7,679&#8201;&#177;&#8201;323</td><td>0.40</td></tr><tr><td>&#160;IVGTT insulin secretion (pmol/l)</td><td>2,059&#8201;&#177;&#8201;131</td><td>1,924&#8201;&#177;&#8201;129</td><td>0.25</td></tr><tr><td>&#160;OGTT insulin secretion (pmol/mmol)</td><td>314&#8201;&#177;&#8201;8</td><td>292&#8201;&#177;&#8201;8</td><td>0.04</td></tr></tbody></table><table-wrap-foot><p textid="31">Data are means&#8201;&#177;&#8201;SEM</p><p textid="32"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test or unpaired <italic>t</italic> test or multivariate linear regression models</p><p textid="33">None of the four other SNPs in TCF7L2 (rs12255372, rs7901695, rs11196205 and rs7895340) affected significantly insulin secretion in the IVGTT (all <italic>p</italic>&#8201;&gt;&#8201;0.2)</p><p textid="34"><sup>a</sup>Adjusted for age, sex and BMI, and insulin sensitivity</p></table-wrap-foot></table-wrap>
###xml 4311 4313 4160 4162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 4564 4565 4413 4414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 4728 4730 4577 4579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 4731 4733 4580 4582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 4760 4761 4609 4610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 4862 4864 4711 4713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 4866 4868 4715 4717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 4869 4871 4718 4720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 4874 4881 4723 4730 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 4881 5090 4730 4939 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Anthropometric and metabolic data of 233 participants who underwent a hyperglycaemic clamp and of 73 participants who underwent a modified hyperglycaemic clamp with additional GLP-1 and arginine administration</p>
###xml 4881 5090 4730 4939 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Anthropometric and metabolic data of 233 participants who underwent a hyperglycaemic clamp and of 73 participants who underwent a modified hyperglycaemic clamp with additional GLP-1 and arginine administration</p></caption>
###xml 5090 5091 4939 4940 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 5091 5098 4940 4947 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Germany</th>
###xml 5098 5123 4947 4972 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">The Netherlands (Utrecht)</th>
###xml 5123 5146 4972 4995 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">The Netherlands (Hoorn)</th>
###xml 5090 5146 4939 4995 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="3">Germany</th><th colspan="3">The Netherlands (Utrecht)</th><th colspan="3">The Netherlands (Hoorn)</th></tr>
###xml 5146 5155 4995 5004 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">rs7903146</th>
###xml 5155 5156 5004 5005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 5155 5162 5004 5011 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 5162 5171 5011 5020 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">rs7903146</th>
###xml 5171 5172 5020 5021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 5171 5178 5020 5027 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 5178 5187 5027 5036 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">rs7903146</th>
###xml 5187 5188 5036 5037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 5187 5194 5036 5043 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 5146 5194 4995 5043 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th></tr>
###xml 5090 5194 4939 5043 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="3">Germany</th><th colspan="3">The Netherlands (Utrecht)</th><th colspan="3">The Netherlands (Hoorn)</th></tr><tr><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th></tr></thead>
###xml 5194 5202 5043 5051 <td xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</td>
###xml 5202 5205 5051 5054 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/C</td>
###xml 5205 5208 5054 5057 <td xmlns:xlink="http://www.w3.org/1999/xlink">X/T</td>
###xml 5208 5208 5057 5057 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 5208 5211 5057 5060 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/C</td>
###xml 5211 5214 5060 5063 <td xmlns:xlink="http://www.w3.org/1999/xlink">X/T</td>
###xml 5214 5214 5063 5063 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 5214 5217 5063 5066 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/C</td>
###xml 5217 5220 5066 5069 <td xmlns:xlink="http://www.w3.org/1999/xlink">X/T</td>
###xml 5220 5220 5069 5069 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 5194 5220 5043 5069 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Genotype</td><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/></tr>
###xml 5220 5237 5069 5086 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex (female/male)</td>
###xml 5237 5242 5086 5091 <td xmlns:xlink="http://www.w3.org/1999/xlink">15/20</td>
###xml 5242 5247 5091 5096 <td xmlns:xlink="http://www.w3.org/1999/xlink">24/14</td>
###xml 5247 5251 5096 5100 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.08</td>
###xml 5251 5255 5100 5104 <td xmlns:xlink="http://www.w3.org/1999/xlink">5/31</td>
###xml 5255 5260 5104 5109 <td xmlns:xlink="http://www.w3.org/1999/xlink">22/11</td>
###xml 5260 5265 5109 5114 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.01</td>
###xml 5265 5270 5114 5119 <td xmlns:xlink="http://www.w3.org/1999/xlink">17/11</td>
###xml 5270 5275 5119 5124 <td xmlns:xlink="http://www.w3.org/1999/xlink">30/33</td>
###xml 5275 5279 5124 5128 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.27</td>
###xml 5220 5279 5069 5128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex (female/male)</td><td>15/20</td><td>24/14</td><td>0.08</td><td>5/31</td><td>22/11</td><td>&lt;0.01</td><td>17/11</td><td>30/33</td><td>0.27</td></tr>
###xml 5279 5286 5128 5135 <td xmlns:xlink="http://www.w3.org/1999/xlink">NGT/IGT</td>
###xml 5286 5290 5135 5139 <td xmlns:xlink="http://www.w3.org/1999/xlink">30/5</td>
###xml 5290 5295 5139 5144 <td xmlns:xlink="http://www.w3.org/1999/xlink">27/11</td>
###xml 5295 5299 5144 5148 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.13</td>
###xml 5299 5303 5148 5152 <td xmlns:xlink="http://www.w3.org/1999/xlink">31/5</td>
###xml 5303 5307 5152 5156 <td xmlns:xlink="http://www.w3.org/1999/xlink">26/7</td>
###xml 5307 5311 5156 5160 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.53</td>
###xml 5311 5315 5160 5164 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/28</td>
###xml 5315 5319 5164 5168 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/66</td>
###xml 5319 5320 5168 5169 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 5279 5320 5128 5169 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>NGT/IGT</td><td>30/5</td><td>27/11</td><td>0.13</td><td>31/5</td><td>26/7</td><td>0.53</td><td>0/28</td><td>0/66</td><td>&#8211;</td></tr>
###xml 5320 5331 5169 5180 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 5331 5339 5180 5186 <td xmlns:xlink="http://www.w3.org/1999/xlink">38&#8201;&#177;&#8201;2</td>
###xml 5339 5347 5186 5192 <td xmlns:xlink="http://www.w3.org/1999/xlink">40&#8201;&#177;&#8201;2</td>
###xml 5347 5351 5192 5196 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.66</td>
###xml 5351 5359 5196 5202 <td xmlns:xlink="http://www.w3.org/1999/xlink">47&#8201;&#177;&#8201;1</td>
###xml 5359 5367 5202 5208 <td xmlns:xlink="http://www.w3.org/1999/xlink">47&#8201;&#177;&#8201;1</td>
###xml 5367 5371 5208 5212 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.94</td>
###xml 5371 5379 5212 5218 <td xmlns:xlink="http://www.w3.org/1999/xlink">56&#8201;&#177;&#8201;1</td>
###xml 5379 5387 5218 5224 <td xmlns:xlink="http://www.w3.org/1999/xlink">58&#8201;&#177;&#8201;1</td>
###xml 5387 5391 5224 5228 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.43</td>
###xml 5320 5391 5169 5228 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>38&#8201;&#177;&#8201;2</td><td>40&#8201;&#177;&#8201;2</td><td>0.66</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>0.94</td><td>56&#8201;&#177;&#8201;1</td><td>58&#8201;&#177;&#8201;1</td><td>0.43</td></tr>
###xml 5400 5401 5237 5238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 5391 5402 5228 5239 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 5402 5414 5239 5249 <td xmlns:xlink="http://www.w3.org/1999/xlink">26.1&#8201;&#177;&#8201;0.9</td>
###xml 5414 5426 5249 5259 <td xmlns:xlink="http://www.w3.org/1999/xlink">25.1&#8201;&#177;&#8201;0.6</td>
###xml 5426 5430 5259 5263 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.41</td>
###xml 5430 5442 5263 5273 <td xmlns:xlink="http://www.w3.org/1999/xlink">25.6&#8201;&#177;&#8201;0.7</td>
###xml 5442 5454 5273 5283 <td xmlns:xlink="http://www.w3.org/1999/xlink">26.2&#8201;&#177;&#8201;0.7</td>
###xml 5454 5458 5283 5287 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.49</td>
###xml 5458 5470 5287 5297 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.2&#8201;&#177;&#8201;0.8</td>
###xml 5470 5482 5297 5307 <td xmlns:xlink="http://www.w3.org/1999/xlink">27.9&#8201;&#177;&#8201;0.4</td>
###xml 5482 5486 5307 5311 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.13</td>
###xml 5391 5486 5228 5311 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td>26.1&#8201;&#177;&#8201;0.9</td><td>25.1&#8201;&#177;&#8201;0.6</td><td>0.41</td><td>25.6&#8201;&#177;&#8201;0.7</td><td>26.2&#8201;&#177;&#8201;0.7</td><td>0.49</td><td>29.2&#8201;&#177;&#8201;0.8</td><td>27.9&#8201;&#177;&#8201;0.4</td><td>0.13</td></tr>
###xml 5486 5509 5311 5334 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="10">Plasma glucose (mmol/l)</td>
###xml 5486 5509 5311 5334 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="10">Plasma glucose (mmol/l)</td></tr>
###xml 5509 5517 5334 5342 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Fasting</td>
###xml 5517 5528 5342 5351 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#8201;&#177;&#8201;0.1</td>
###xml 5528 5539 5351 5360 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.0&#8201;&#177;&#8201;0.1</td>
###xml 5539 5543 5360 5364 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.72</td>
###xml 5543 5554 5364 5373 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.6&#8201;&#177;&#8201;0.1</td>
###xml 5554 5565 5373 5382 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.8&#8201;&#177;&#8201;0.1</td>
###xml 5565 5569 5382 5386 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.18</td>
###xml 5569 5580 5386 5395 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.6&#8201;&#177;&#8201;0.1</td>
###xml 5580 5591 5395 5404 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.6&#8201;&#177;&#8201;0.1</td>
###xml 5591 5595 5404 5408 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.75</td>
###xml 5509 5595 5334 5408 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Fasting</td><td>5.1&#8201;&#177;&#8201;0.1</td><td>5.0&#8201;&#177;&#8201;0.1</td><td>0.72</td><td>4.6&#8201;&#177;&#8201;0.1</td><td>4.8&#8201;&#177;&#8201;0.1</td><td>0.18</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>0.75</td></tr>
###xml 5595 5607 5408 5420 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;2&#160;h glucose</td>
###xml 5607 5618 5420 5429 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.9&#8201;&#177;&#8201;0.3</td>
###xml 5618 5629 5429 5438 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.5&#8201;&#177;&#8201;0.3</td>
###xml 5629 5633 5438 5442 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.21</td>
###xml 5633 5644 5442 5451 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.7&#8201;&#177;&#8201;0.3</td>
###xml 5644 5655 5451 5460 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.6&#8201;&#177;&#8201;0.3</td>
###xml 5655 5659 5460 5464 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.74</td>
###xml 5659 5670 5464 5473 <td xmlns:xlink="http://www.w3.org/1999/xlink">9.5&#8201;&#177;&#8201;0.1</td>
###xml 5670 5681 5473 5482 <td xmlns:xlink="http://www.w3.org/1999/xlink">9.5&#8201;&#177;&#8201;0.1</td>
###xml 5681 5685 5482 5486 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.84</td>
###xml 5595 5685 5408 5486 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;2&#160;h glucose</td><td>5.9&#8201;&#177;&#8201;0.3</td><td>6.5&#8201;&#177;&#8201;0.3</td><td>0.21</td><td>5.7&#8201;&#177;&#8201;0.3</td><td>5.6&#8201;&#177;&#8201;0.3</td><td>0.74</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>0.84</td></tr>
###xml 5714 5716 5514 5516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 5720 5722 5520 5522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 5731 5733 5531 5533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 5685 5734 5486 5534 <td xmlns:xlink="http://www.w3.org/1999/xlink">Insulin sensitivity (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td>
###xml 5734 5747 5534 5545 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.15&#8201;&#177;&#8201;0.02</td>
###xml 5747 5760 5545 5556 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.15&#8201;&#177;&#8201;0.01</td>
###xml 5760 5764 5556 5560 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.90</td>
###xml 5764 5777 5560 5571 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.17&#8201;&#177;&#8201;0.02</td>
###xml 5777 5790 5571 5582 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.18&#8201;&#177;&#8201;0.02</td>
###xml 5790 5794 5582 5586 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.60</td>
###xml 5794 5807 5586 5597 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.11&#8201;&#177;&#8201;0.01</td>
###xml 5807 5820 5597 5608 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.14&#8201;&#177;&#8201;0.01</td>
###xml 5820 5824 5608 5612 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.21</td>
###xml 5685 5824 5486 5612 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Insulin sensitivity (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.15&#8201;&#177;&#8201;0.02</td><td>0.15&#8201;&#177;&#8201;0.01</td><td>0.90</td><td>0.17&#8201;&#177;&#8201;0.02</td><td>0.18&#8201;&#177;&#8201;0.02</td><td>0.60</td><td>0.11&#8201;&#177;&#8201;0.01</td><td>0.14&#8201;&#177;&#8201;0.01</td><td>0.21</td></tr>
###xml 5856 5857 5644 5645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 5824 5857 5612 5645 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="10">Insulin secretion index (pmol/l)<sup>a</sup></td>
###xml 5824 5857 5612 5645 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="10">Insulin secretion index (pmol/l)<sup>a</sup></td></tr>
###xml 5857 5884 5645 5672 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;First phase (sum 0&#8211;10&#160;min)</td>
###xml 5884 5897 5672 5683 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,067&#8201;&#177;&#8201;158</td>
###xml 5897 5908 5683 5692 <td xmlns:xlink="http://www.w3.org/1999/xlink">815&#8201;&#177;&#8201;105</td>
###xml 5908 5912 5692 5696 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.18</td>
###xml 5912 5922 5696 5704 <td xmlns:xlink="http://www.w3.org/1999/xlink">963&#8201;&#177;&#8201;75</td>
###xml 5922 5932 5704 5712 <td xmlns:xlink="http://www.w3.org/1999/xlink">891&#8201;&#177;&#8201;96</td>
###xml 5932 5936 5712 5716 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.76</td>
###xml 5936 5946 5716 5724 <td xmlns:xlink="http://www.w3.org/1999/xlink">699&#8201;&#177;&#8201;70</td>
###xml 5946 5956 5724 5732 <td xmlns:xlink="http://www.w3.org/1999/xlink">679&#8201;&#177;&#8201;72</td>
###xml 5956 5960 5732 5736 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.68</td>
###xml 5857 5960 5645 5736 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;First phase (sum 0&#8211;10&#160;min)</td><td>1,067&#8201;&#177;&#8201;158</td><td>815&#8201;&#177;&#8201;105</td><td>0.18</td><td>963&#8201;&#177;&#8201;75</td><td>891&#8201;&#177;&#8201;96</td><td>0.76</td><td>699&#8201;&#177;&#8201;70</td><td>679&#8201;&#177;&#8201;72</td><td>0.68</td></tr>
###xml 5960 5973 5736 5749 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Second phase</td>
###xml 5973 5983 5749 5757 <td xmlns:xlink="http://www.w3.org/1999/xlink">308&#8201;&#177;&#8201;47</td>
###xml 5983 5993 5757 5765 <td xmlns:xlink="http://www.w3.org/1999/xlink">291&#8201;&#177;&#8201;41</td>
###xml 5993 5997 5765 5769 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.80</td>
###xml 5997 6007 5769 5777 <td xmlns:xlink="http://www.w3.org/1999/xlink">389&#8201;&#177;&#8201;42</td>
###xml 6007 6017 5777 5785 <td xmlns:xlink="http://www.w3.org/1999/xlink">376&#8201;&#177;&#8201;47</td>
###xml 6017 6021 5785 5789 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.71</td>
###xml 6021 6031 5789 5797 <td xmlns:xlink="http://www.w3.org/1999/xlink">304&#8201;&#177;&#8201;45</td>
###xml 6031 6041 5797 5805 <td xmlns:xlink="http://www.w3.org/1999/xlink">303&#8201;&#177;&#8201;38</td>
###xml 6041 6045 5805 5809 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.18</td>
###xml 5960 6045 5736 5809 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Second phase</td><td>308&#8201;&#177;&#8201;47</td><td>291&#8201;&#177;&#8201;41</td><td>0.80</td><td>389&#8201;&#177;&#8201;42</td><td>376&#8201;&#177;&#8201;47</td><td>0.71</td><td>304&#8201;&#177;&#8201;45</td><td>303&#8201;&#177;&#8201;38</td><td>0.18</td></tr>
###xml 6045 6063 5809 5827 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;First phase GLP-1</td>
###xml 6063 6076 5827 5838 <td xmlns:xlink="http://www.w3.org/1999/xlink">2,049&#8201;&#177;&#8201;258</td>
###xml 6076 6089 5838 5849 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,466&#8201;&#177;&#8201;175</td>
###xml 6089 6093 5849 5853 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.03</td>
###xml 6093 6097 5853 5857 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6097 6101 5857 5861 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6101 6101 5861 5861 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 6101 6105 5861 5865 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6105 6109 5865 5869 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6109 6109 5869 5869 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 6045 6109 5809 5869 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;First phase GLP-1</td><td>2,049&#8201;&#177;&#8201;258</td><td>1,466&#8201;&#177;&#8201;175</td><td>0.03</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr>
###xml 6109 6128 5869 5888 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Second phase GLP-1</td>
###xml 6128 6141 5888 5899 <td xmlns:xlink="http://www.w3.org/1999/xlink">4,567&#8201;&#177;&#8201;568</td>
###xml 6141 6154 5899 5910 <td xmlns:xlink="http://www.w3.org/1999/xlink">2,881&#8201;&#177;&#8201;341</td>
###xml 6154 6159 5910 5915 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.006</td>
###xml 6159 6163 5915 5919 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6163 6167 5919 5923 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6167 6167 5923 5923 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 6167 6171 5923 5927 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6171 6175 5927 5931 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6175 6175 5931 5931 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 6109 6175 5869 5931 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Second phase GLP-1</td><td>4,567&#8201;&#177;&#8201;568</td><td>2,881&#8201;&#177;&#8201;341</td><td>0.006</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr>
###xml 6175 6184 5931 5940 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Arginine</td>
###xml 6184 6197 5940 5951 <td xmlns:xlink="http://www.w3.org/1999/xlink">2,680&#8201;&#177;&#8201;226</td>
###xml 6197 6210 5951 5962 <td xmlns:xlink="http://www.w3.org/1999/xlink">2,252&#8201;&#177;&#8201;181</td>
###xml 6210 6214 5962 5966 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.40</td>
###xml 6214 6218 5966 5970 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6218 6222 5970 5974 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6222 6222 5974 5974 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 6222 6226 5974 5978 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6226 6230 5978 5982 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</td>
###xml 6230 6230 5982 5982 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 6175 6230 5931 5982 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Arginine</td><td>2,680&#8201;&#177;&#8201;226</td><td>2,252&#8201;&#177;&#8201;181</td><td>0.40</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr>
###xml 5194 6230 5043 5982 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Genotype</td><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/></tr><tr><td>Sex (female/male)</td><td>15/20</td><td>24/14</td><td>0.08</td><td>5/31</td><td>22/11</td><td>&lt;0.01</td><td>17/11</td><td>30/33</td><td>0.27</td></tr><tr><td>NGT/IGT</td><td>30/5</td><td>27/11</td><td>0.13</td><td>31/5</td><td>26/7</td><td>0.53</td><td>0/28</td><td>0/66</td><td>&#8211;</td></tr><tr><td>Age (years)</td><td>38&#8201;&#177;&#8201;2</td><td>40&#8201;&#177;&#8201;2</td><td>0.66</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>0.94</td><td>56&#8201;&#177;&#8201;1</td><td>58&#8201;&#177;&#8201;1</td><td>0.43</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26.1&#8201;&#177;&#8201;0.9</td><td>25.1&#8201;&#177;&#8201;0.6</td><td>0.41</td><td>25.6&#8201;&#177;&#8201;0.7</td><td>26.2&#8201;&#177;&#8201;0.7</td><td>0.49</td><td>29.2&#8201;&#177;&#8201;0.8</td><td>27.9&#8201;&#177;&#8201;0.4</td><td>0.13</td></tr><tr><td colspan="10">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting</td><td>5.1&#8201;&#177;&#8201;0.1</td><td>5.0&#8201;&#177;&#8201;0.1</td><td>0.72</td><td>4.6&#8201;&#177;&#8201;0.1</td><td>4.8&#8201;&#177;&#8201;0.1</td><td>0.18</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>0.75</td></tr><tr><td>&#160;2&#160;h glucose</td><td>5.9&#8201;&#177;&#8201;0.3</td><td>6.5&#8201;&#177;&#8201;0.3</td><td>0.21</td><td>5.7&#8201;&#177;&#8201;0.3</td><td>5.6&#8201;&#177;&#8201;0.3</td><td>0.74</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>0.84</td></tr><tr><td>Insulin sensitivity (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.15&#8201;&#177;&#8201;0.02</td><td>0.15&#8201;&#177;&#8201;0.01</td><td>0.90</td><td>0.17&#8201;&#177;&#8201;0.02</td><td>0.18&#8201;&#177;&#8201;0.02</td><td>0.60</td><td>0.11&#8201;&#177;&#8201;0.01</td><td>0.14&#8201;&#177;&#8201;0.01</td><td>0.21</td></tr><tr><td colspan="10">Insulin secretion index (pmol/l)<sup>a</sup></td></tr><tr><td>&#160;First phase (sum 0&#8211;10&#160;min)</td><td>1,067&#8201;&#177;&#8201;158</td><td>815&#8201;&#177;&#8201;105</td><td>0.18</td><td>963&#8201;&#177;&#8201;75</td><td>891&#8201;&#177;&#8201;96</td><td>0.76</td><td>699&#8201;&#177;&#8201;70</td><td>679&#8201;&#177;&#8201;72</td><td>0.68</td></tr><tr><td>&#160;Second phase</td><td>308&#8201;&#177;&#8201;47</td><td>291&#8201;&#177;&#8201;41</td><td>0.80</td><td>389&#8201;&#177;&#8201;42</td><td>376&#8201;&#177;&#8201;47</td><td>0.71</td><td>304&#8201;&#177;&#8201;45</td><td>303&#8201;&#177;&#8201;38</td><td>0.18</td></tr><tr><td>&#160;First phase GLP-1</td><td>2,049&#8201;&#177;&#8201;258</td><td>1,466&#8201;&#177;&#8201;175</td><td>0.03</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr><tr><td>&#160;Second phase GLP-1</td><td>4,567&#8201;&#177;&#8201;568</td><td>2,881&#8201;&#177;&#8201;341</td><td>0.006</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr><tr><td>&#160;Arginine</td><td>2,680&#8201;&#177;&#8201;226</td><td>2,252&#8201;&#177;&#8201;181</td><td>0.40</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr></tbody>
###xml 5090 6230 4939 5982 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">Germany</th><th colspan="3">The Netherlands (Utrecht)</th><th colspan="3">The Netherlands (Hoorn)</th></tr><tr><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/></tr><tr><td>Sex (female/male)</td><td>15/20</td><td>24/14</td><td>0.08</td><td>5/31</td><td>22/11</td><td>&lt;0.01</td><td>17/11</td><td>30/33</td><td>0.27</td></tr><tr><td>NGT/IGT</td><td>30/5</td><td>27/11</td><td>0.13</td><td>31/5</td><td>26/7</td><td>0.53</td><td>0/28</td><td>0/66</td><td>&#8211;</td></tr><tr><td>Age (years)</td><td>38&#8201;&#177;&#8201;2</td><td>40&#8201;&#177;&#8201;2</td><td>0.66</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>0.94</td><td>56&#8201;&#177;&#8201;1</td><td>58&#8201;&#177;&#8201;1</td><td>0.43</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26.1&#8201;&#177;&#8201;0.9</td><td>25.1&#8201;&#177;&#8201;0.6</td><td>0.41</td><td>25.6&#8201;&#177;&#8201;0.7</td><td>26.2&#8201;&#177;&#8201;0.7</td><td>0.49</td><td>29.2&#8201;&#177;&#8201;0.8</td><td>27.9&#8201;&#177;&#8201;0.4</td><td>0.13</td></tr><tr><td colspan="10">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting</td><td>5.1&#8201;&#177;&#8201;0.1</td><td>5.0&#8201;&#177;&#8201;0.1</td><td>0.72</td><td>4.6&#8201;&#177;&#8201;0.1</td><td>4.8&#8201;&#177;&#8201;0.1</td><td>0.18</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>0.75</td></tr><tr><td>&#160;2&#160;h glucose</td><td>5.9&#8201;&#177;&#8201;0.3</td><td>6.5&#8201;&#177;&#8201;0.3</td><td>0.21</td><td>5.7&#8201;&#177;&#8201;0.3</td><td>5.6&#8201;&#177;&#8201;0.3</td><td>0.74</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>0.84</td></tr><tr><td>Insulin sensitivity (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.15&#8201;&#177;&#8201;0.02</td><td>0.15&#8201;&#177;&#8201;0.01</td><td>0.90</td><td>0.17&#8201;&#177;&#8201;0.02</td><td>0.18&#8201;&#177;&#8201;0.02</td><td>0.60</td><td>0.11&#8201;&#177;&#8201;0.01</td><td>0.14&#8201;&#177;&#8201;0.01</td><td>0.21</td></tr><tr><td colspan="10">Insulin secretion index (pmol/l)<sup>a</sup></td></tr><tr><td>&#160;First phase (sum 0&#8211;10&#160;min)</td><td>1,067&#8201;&#177;&#8201;158</td><td>815&#8201;&#177;&#8201;105</td><td>0.18</td><td>963&#8201;&#177;&#8201;75</td><td>891&#8201;&#177;&#8201;96</td><td>0.76</td><td>699&#8201;&#177;&#8201;70</td><td>679&#8201;&#177;&#8201;72</td><td>0.68</td></tr><tr><td>&#160;Second phase</td><td>308&#8201;&#177;&#8201;47</td><td>291&#8201;&#177;&#8201;41</td><td>0.80</td><td>389&#8201;&#177;&#8201;42</td><td>376&#8201;&#177;&#8201;47</td><td>0.71</td><td>304&#8201;&#177;&#8201;45</td><td>303&#8201;&#177;&#8201;38</td><td>0.18</td></tr><tr><td>&#160;First phase GLP-1</td><td>2,049&#8201;&#177;&#8201;258</td><td>1,466&#8201;&#177;&#8201;175</td><td>0.03</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr><tr><td>&#160;Second phase GLP-1</td><td>4,567&#8201;&#177;&#8201;568</td><td>2,881&#8201;&#177;&#8201;341</td><td>0.006</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr><tr><td>&#160;Arginine</td><td>2,680&#8201;&#177;&#8201;226</td><td>2,252&#8201;&#177;&#8201;181</td><td>0.40</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr></tbody></table>
###xml 6230 6249 5982 5999 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Data are means&#177;SE</p>
###xml 6249 6250 5999 6000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 6278 6281 6028 6029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 6281 6282 6029 6030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 6298 6299 6046 6047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 6249 6345 5999 6093 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test, unpaired <italic>t</italic> test or multivariate linear regression models</p>
###xml 6420 6421 6168 6169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 6448 6449 6196 6197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 6345 6490 6093 6238 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">Carriers of the risk allele for SNP rs12255372 showed reduced first phase (<italic>p</italic>&#8201;=&#8201;0.02) and second phase (<italic>p</italic>&#8201;=&#8201;0.005) GLP-1-induced insulin secretion</p>
###xml 6565 6566 6313 6314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 6490 6606 6238 6354 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Carriers of the risk allele for SNP rs7901695 showed reduced second phase (<italic>p</italic>&#8201;=&#8201;0.02) GLP-1-induced insulin secretion</p>
###xml 6606 6610 6354 6358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</italic>
###xml 6606 6624 6354 6372 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><italic>n.a.</italic> Not available</p>
###xml 6624 6625 6372 6373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 6624 6679 6372 6427 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41"><sup>a</sup>Adjusted for age, sex and BMI, and insulin sensitivity</p>
###xml 6230 6679 5982 6427 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Data are means&#177;SE</p><p textid="37"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test, unpaired <italic>t</italic> test or multivariate linear regression models</p><p textid="38">Carriers of the risk allele for SNP rs12255372 showed reduced first phase (<italic>p</italic>&#8201;=&#8201;0.02) and second phase (<italic>p</italic>&#8201;=&#8201;0.005) GLP-1-induced insulin secretion</p><p textid="39">Carriers of the risk allele for SNP rs7901695 showed reduced second phase (<italic>p</italic>&#8201;=&#8201;0.02) GLP-1-induced insulin secretion</p><p textid="40"><italic>n.a.</italic> Not available</p><p textid="41"><sup>a</sup>Adjusted for age, sex and BMI, and insulin sensitivity</p></table-wrap-foot>
###xml 4874 6679 4723 6427 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="35">Anthropometric and metabolic data of 233 participants who underwent a hyperglycaemic clamp and of 73 participants who underwent a modified hyperglycaemic clamp with additional GLP-1 and arginine administration</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">Germany</th><th colspan="3">The Netherlands (Utrecht)</th><th colspan="3">The Netherlands (Hoorn)</th></tr><tr><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th><th colspan="2">rs7903146</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Genotype</td><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/><td>C/C</td><td>X/T</td><td/></tr><tr><td>Sex (female/male)</td><td>15/20</td><td>24/14</td><td>0.08</td><td>5/31</td><td>22/11</td><td>&lt;0.01</td><td>17/11</td><td>30/33</td><td>0.27</td></tr><tr><td>NGT/IGT</td><td>30/5</td><td>27/11</td><td>0.13</td><td>31/5</td><td>26/7</td><td>0.53</td><td>0/28</td><td>0/66</td><td>&#8211;</td></tr><tr><td>Age (years)</td><td>38&#8201;&#177;&#8201;2</td><td>40&#8201;&#177;&#8201;2</td><td>0.66</td><td>47&#8201;&#177;&#8201;1</td><td>47&#8201;&#177;&#8201;1</td><td>0.94</td><td>56&#8201;&#177;&#8201;1</td><td>58&#8201;&#177;&#8201;1</td><td>0.43</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26.1&#8201;&#177;&#8201;0.9</td><td>25.1&#8201;&#177;&#8201;0.6</td><td>0.41</td><td>25.6&#8201;&#177;&#8201;0.7</td><td>26.2&#8201;&#177;&#8201;0.7</td><td>0.49</td><td>29.2&#8201;&#177;&#8201;0.8</td><td>27.9&#8201;&#177;&#8201;0.4</td><td>0.13</td></tr><tr><td colspan="10">Plasma glucose (mmol/l)</td></tr><tr><td>&#160;Fasting</td><td>5.1&#8201;&#177;&#8201;0.1</td><td>5.0&#8201;&#177;&#8201;0.1</td><td>0.72</td><td>4.6&#8201;&#177;&#8201;0.1</td><td>4.8&#8201;&#177;&#8201;0.1</td><td>0.18</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>6.6&#8201;&#177;&#8201;0.1</td><td>0.75</td></tr><tr><td>&#160;2&#160;h glucose</td><td>5.9&#8201;&#177;&#8201;0.3</td><td>6.5&#8201;&#177;&#8201;0.3</td><td>0.21</td><td>5.7&#8201;&#177;&#8201;0.3</td><td>5.6&#8201;&#177;&#8201;0.3</td><td>0.74</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>9.5&#8201;&#177;&#8201;0.1</td><td>0.84</td></tr><tr><td>Insulin sensitivity (&#956;mol kg<sup>&#8722;1</sup> min<sup>&#8722;1</sup> [pmol/l]<sup>&#8722;1</sup>)</td><td>0.15&#8201;&#177;&#8201;0.02</td><td>0.15&#8201;&#177;&#8201;0.01</td><td>0.90</td><td>0.17&#8201;&#177;&#8201;0.02</td><td>0.18&#8201;&#177;&#8201;0.02</td><td>0.60</td><td>0.11&#8201;&#177;&#8201;0.01</td><td>0.14&#8201;&#177;&#8201;0.01</td><td>0.21</td></tr><tr><td colspan="10">Insulin secretion index (pmol/l)<sup>a</sup></td></tr><tr><td>&#160;First phase (sum 0&#8211;10&#160;min)</td><td>1,067&#8201;&#177;&#8201;158</td><td>815&#8201;&#177;&#8201;105</td><td>0.18</td><td>963&#8201;&#177;&#8201;75</td><td>891&#8201;&#177;&#8201;96</td><td>0.76</td><td>699&#8201;&#177;&#8201;70</td><td>679&#8201;&#177;&#8201;72</td><td>0.68</td></tr><tr><td>&#160;Second phase</td><td>308&#8201;&#177;&#8201;47</td><td>291&#8201;&#177;&#8201;41</td><td>0.80</td><td>389&#8201;&#177;&#8201;42</td><td>376&#8201;&#177;&#8201;47</td><td>0.71</td><td>304&#8201;&#177;&#8201;45</td><td>303&#8201;&#177;&#8201;38</td><td>0.18</td></tr><tr><td>&#160;First phase GLP-1</td><td>2,049&#8201;&#177;&#8201;258</td><td>1,466&#8201;&#177;&#8201;175</td><td>0.03</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr><tr><td>&#160;Second phase GLP-1</td><td>4,567&#8201;&#177;&#8201;568</td><td>2,881&#8201;&#177;&#8201;341</td><td>0.006</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr><tr><td>&#160;Arginine</td><td>2,680&#8201;&#177;&#8201;226</td><td>2,252&#8201;&#177;&#8201;181</td><td>0.40</td><td>n.a.</td><td>n.a.</td><td/><td>n.a.</td><td>n.a.</td><td/></tr></tbody></table><table-wrap-foot><p textid="36">Data are means&#177;SE</p><p textid="37"><italic>p</italic> values were obtained using <italic>&#967;</italic><sup>2</sup> test, unpaired <italic>t</italic> test or multivariate linear regression models</p><p textid="38">Carriers of the risk allele for SNP rs12255372 showed reduced first phase (<italic>p</italic>&#8201;=&#8201;0.02) and second phase (<italic>p</italic>&#8201;=&#8201;0.005) GLP-1-induced insulin secretion</p><p textid="39">Carriers of the risk allele for SNP rs7901695 showed reduced second phase (<italic>p</italic>&#8201;=&#8201;0.02) GLP-1-induced insulin secretion</p><p textid="40"><italic>n.a.</italic> Not available</p><p textid="41"><sup>a</sup>Adjusted for age, sex and BMI, and insulin sensitivity</p></table-wrap-foot></table-wrap>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 43 55 <span type="species:ncbi:9606">participants</span>
###xml 141 153 <span type="species:ncbi:9606">participants</span>
###xml 239 251 <span type="species:ncbi:9606">participants</span>
###xml 436 448 <span type="species:ncbi:9606">participants</span>
###xml 1809 1821 <span type="species:ncbi:9606">participants</span>
###xml 3134 3146 <span type="species:ncbi:9606">participants</span>
###xml 3364 3376 <span type="species:ncbi:9606">participants</span>
###xml 4258 4270 <span type="species:ncbi:9606">participants</span>
###xml 4320 4332 <span type="species:ncbi:9606">participants</span>
###xml 4480 4492 <span type="species:ncbi:9606">participants</span>
###xml 4539 4551 <span type="species:ncbi:9606">participants</span>
###xml 4572 4584 <span type="species:ncbi:9606">participants</span>
###xml 4922 4934 <span type="species:ncbi:9606">participants</span>
###xml 4982 4994 <span type="species:ncbi:9606">participants</span>
###xml 6683 6695 <span type="species:ncbi:9606">participants</span>
###xml 6791 6803 <span type="species:ncbi:9606">participants</span>
Participants We studied 1,110 non-diabetic participants by an OGTT (Table 1). Secretion patterns of GLP-1 were obtained in a subgroup of 155 participants. The anthropometric characteristics of this subgroup are shown in Table 2. All 1,110 participants were also genotyped for the following five SNPs in the TCF7L2 gene: rs7903146, rs12255372, rs7901695, rs11196205 and rs7895340. Table 1Anthropometric and metabolic data from all 1,110 participants who underwent an OGTT rs7903146p value (ANOVA)p value (CC vs XT)GenotypeC/CC/TT/Tn54647490NGT/IGT461/85386/8863/270.0070.03Sex (female/male)346/200315/15950/400.130.64Age (years)39 +/- 140 +/- 141 +/- 10.390.67BMI (kg/m2)29.5 +/- 0.428.9 +/- 0.428.2 +/- 1.00.510.24Plasma glucose (mmol/l) Fasting 5.1 +/- 0.025.1 +/- 0.025.2 +/- 0.070.250.39 2 h 6.1 +/- 0.076.2 +/- 0.076.7 +/- 0.20.060.17Plasma insulin (pmol/l) Fasting62.0 +/- 2.153.4 +/- 1.749.8 +/- 3.10.0040.001 2 h442 +/- 19356 +/- 17372 +/- 340.120.04Insulin sensitivityOGTT (arbitrary units)16.8 +/- 0.518.2 +/- 0.517.8 +/- 1.20.02/0.02a0.005/0.006aInsulin secretionOGTT (pmol/mmol)319 +/- 5301 +/- 5292 +/- 100.003/0.04b0.0009/0.02bInsulin/glucose ratio (pmol/mmol)143 +/- 5127 +/- 5124 +/- 130.003/0.03b0.001/0.01bData are means +/- SEMp values were obtained using chi2 test or ANOVAAnalysis for rs12255372 and rs7901695 also revealed a significant difference in insulin secretion (p = 0.003 and p = 0.05), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (p = 0.53 and 0.45)ap values are derived from multivariate linear regression models: adjusted for age, sex and BMIbp values are derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivityTable 2Anthropometric and metabolic data of the subgroup of 155 participants with additional measurements of GLP-1 rs7903146p value (ANOVA)p value (CC vs XT)GenotypeC/CC/TT/Tn736715NGT/IGT64/948/1910/50.030.009Sex (female/male)50/2342/258/70.500.33Age (years)46 +/- 147 +/- 147 +/- 30.990.96BMI (kg/m2)29.8 +/- 0.730.3 +/- 0.727.1 +/- 1.10.150.88Plasma glucose (mmol/l) Fasting5.2 +/- 0.055.3 +/- 0.075.6 +/- 0.20.170.21 2 h6.5 +/- 0.17.0 +/- 0.27.2 +/- 0.50.220.10Insulin sensitivityOGTT (arbitrary units) 12.8 +/- 0.713.6 +/- 1.015.7 +/- 2.60.74/0.92a0.78/0.75aInsulin secretionOGTT (pmol/mmol)304 +/- 12287 +/- 13235 +/- 190.01/0.02b0.02/0.01bGLP-1 (pmol/l) 0 min 16.1 +/- 0.917.3 +/- 1.317.3 +/- 2.00.910.88 30 min34.1 +/- 2.138.8 +/- 4.038.1 +/- 3.50.450.36 120 min28.9 +/- 1.529.0 +/- 1.728.9 +/- 2.40.870.88 Fold increase 0-30 min2.5 +/- 0.22.7 +/- 0.32.4 +/- 0.40.770.84Data are means +/- SEMp values were obtained using chi2 test or ANOVAAnalysis for rs7901695 also revealed a significant difference in insulin secretion (p = 0.02), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (p = 0.73 and 0.76)ap values were derived from multivariate linear regression models: adjusted for age, sex and BMIbp values were derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivityA subset of 210 participants were studied by an IVGTT combined with a euglycaemic-hyperinsulinaemic clamp to determine insulin secretion capacity and insulin sensitivity in one test [16] (Table 3). Table 3Anthropometric and metabolic data of 210 participants who underwent a combined IVGTT and hyperinsulinaemic-euglycaemic clamp rs7903146p value (CC vs XT)GenotypeC/CX/Tn97113NGT/IGT80/1781/320.06Sex (female/male)59/3864/490.58Age (years)44 +/- 145 +/- 10.29BMI (kg/m2)29.0 +/- 0.528.8 +/- 0.50.82Insulin sensitivityclamp (mumol kg-1 min-1 [pmol/l]-1)0.07 +/- 0.010.07 +/- 0.010.77Insulin secretion indexa IVGTT C-peptide secretion (pmol/l)7,904 +/- 3067,679 +/- 3230.40 IVGTT insulin secretion (pmol/l)2,059 +/- 1311,924 +/- 1290.25 OGTT insulin secretion (pmol/mmol)314 +/- 8292 +/- 80.04Data are means +/- SEMp values were obtained using chi2 test or unpaired t test or multivariate linear regression modelsNone of the four other SNPs in TCF7L2 (rs12255372, rs7901695, rs11196205 and rs7895340) affected significantly insulin secretion in the IVGTT (all p > 0.2)aAdjusted for age, sex and BMI, and insulin sensitivityAdditionally, 233 participants were studied by a hyperglycaemic clamp [17]. The participants were selected from three independent studies in the Netherlands and Germany. The German and the Dutch cohort from Utrecht consisted of NGT and IGT participants, the Dutch cohort from Hoorn consisted of IGT participants only (Table 4). All participants in our studies underwent a standard OGTT to define their glucose tolerance status. Details of the study groups have been described previously [17-19]. In the German subgroup (n = 73), the hyperglycaemic clamp was continued with an additional GLP-1 and arginine administration [15, 20-22]. Table 4Anthropometric and metabolic data of 233 participants who underwent a hyperglycaemic clamp and of 73 participants who underwent a modified hyperglycaemic clamp with additional GLP-1 and arginine administration GermanyThe Netherlands (Utrecht)The Netherlands (Hoorn)rs7903146p valuers7903146p valuers7903146p valueGenotypeC/CX/TC/CX/TC/CX/TSex (female/male)15/2024/140.085/3122/11<0.0117/1130/330.27NGT/IGT30/527/110.1331/526/70.530/280/66-Age (years)38 +/- 240 +/- 20.6647 +/- 147 +/- 10.9456 +/- 158 +/- 10.43BMI (kg/m2)26.1 +/- 0.925.1 +/- 0.60.4125.6 +/- 0.726.2 +/- 0.70.4929.2 +/- 0.827.9 +/- 0.40.13Plasma glucose (mmol/l) Fasting5.1 +/- 0.15.0 +/- 0.10.724.6 +/- 0.14.8 +/- 0.10.186.6 +/- 0.16.6 +/- 0.10.75 2 h glucose5.9 +/- 0.36.5 +/- 0.30.215.7 +/- 0.35.6 +/- 0.30.749.5 +/- 0.19.5 +/- 0.10.84Insulin sensitivity (mumol kg-1 min-1 [pmol/l]-1)0.15 +/- 0.020.15 +/- 0.010.900.17 +/- 0.020.18 +/- 0.020.600.11 +/- 0.010.14 +/- 0.010.21Insulin secretion index (pmol/l)a First phase (sum 0-10 min)1,067 +/- 158815 +/- 1050.18963 +/- 75891 +/- 960.76699 +/- 70679 +/- 720.68 Second phase308 +/- 47291 +/- 410.80389 +/- 42376 +/- 470.71304 +/- 45303 +/- 380.18 First phase GLP-12,049 +/- 2581,466 +/- 1750.03n.a.n.a.n.a.n.a. Second phase GLP-14,567 +/- 5682,881 +/- 3410.006n.a.n.a.n.a.n.a. Arginine2,680 +/- 2262,252 +/- 1810.40n.a.n.a.n.a.n.a.Data are means+/-SEp values were obtained using chi2 test, unpaired t test or multivariate linear regression modelsCarriers of the risk allele for SNP rs12255372 showed reduced first phase (p = 0.02) and second phase (p = 0.005) GLP-1-induced insulin secretionCarriers of the risk allele for SNP rs7901695 showed reduced second phase (p = 0.02) GLP-1-induced insulin secretionn.a. Not availableaAdjusted for age, sex and BMI, and insulin sensitivityThe participants were not related to each other. Informed written consent for all studies was obtained from all participants, and the local ethics committee approved the protocols.
###end p 17
###begin p 18
###xml 49 61 <span type="species:ncbi:9606">participants</span>
Anthropometric and metabolic data from all 1,110 participants who underwent an OGTT
###end p 18
###begin p 19
Data are means +/- SEM
###end p 19
###begin p 20
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 29 32 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 32 33 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
p values were obtained using chi2 test or ANOVA
###end p 20
###begin p 21
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Analysis for rs12255372 and rs7901695 also revealed a significant difference in insulin secretion (p = 0.003 and p = 0.05), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (p = 0.53 and 0.45)
###end p 21
###begin p 22
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
ap values are derived from multivariate linear regression models: adjusted for age, sex and BMI
###end p 22
###begin p 23
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
bp values are derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity
###end p 23
###begin p 24
###xml 57 69 <span type="species:ncbi:9606">participants</span>
Anthropometric and metabolic data of the subgroup of 155 participants with additional measurements of GLP-1
###end p 24
###begin p 25
Data are means +/- SEM
###end p 25
###begin p 26
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 29 32 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 32 33 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
p values were obtained using chi2 test or ANOVA
###end p 26
###begin p 27
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Analysis for rs7901695 also revealed a significant difference in insulin secretion (p = 0.02), whereas for rs7895340 and rs11196205 no significant differences in insulin secretion were detected (p = 0.73 and 0.76)
###end p 27
###begin p 28
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
ap values were derived from multivariate linear regression models: adjusted for age, sex and BMI
###end p 28
###begin p 29
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
bp values were derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity
###end p 29
###begin p 30
###xml 41 53 <span type="species:ncbi:9606">participants</span>
Anthropometric and metabolic data of 210 participants who underwent a combined IVGTT and hyperinsulinaemic-euglycaemic clamp
###end p 30
###begin p 31
Data are means +/- SEM
###end p 31
###begin p 32
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 29 32 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 32 33 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 51 52 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
p values were obtained using chi2 test or unpaired t test or multivariate linear regression models
###end p 32
###begin p 33
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
None of the four other SNPs in TCF7L2 (rs12255372, rs7901695, rs11196205 and rs7895340) affected significantly insulin secretion in the IVGTT (all p > 0.2)
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aAdjusted for age, sex and BMI, and insulin sensitivity
###end p 34
###begin p 35
###xml 41 53 <span type="species:ncbi:9606">participants</span>
###xml 101 113 <span type="species:ncbi:9606">participants</span>
Anthropometric and metabolic data of 233 participants who underwent a hyperglycaemic clamp and of 73 participants who underwent a modified hyperglycaemic clamp with additional GLP-1 and arginine administration
###end p 35
###begin p 36
Data are means+/-SE
###end p 36
###begin p 37
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 29 32 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 32 33 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 49 50 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
p values were obtained using chi2 test, unpaired t test or multivariate linear regression models
###end p 37
###begin p 38
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Carriers of the risk allele for SNP rs12255372 showed reduced first phase (p = 0.02) and second phase (p = 0.005) GLP-1-induced insulin secretion
###end p 38
###begin p 39
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Carriers of the risk allele for SNP rs7901695 showed reduced second phase (p = 0.02) GLP-1-induced insulin secretion
###end p 39
###begin p 40
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</italic>
n.a. Not available
###end p 40
###begin p 41
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aAdjusted for age, sex and BMI, and insulin sensitivity
###end p 41
###begin p 42
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genotyping</bold>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 76 77 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
Genotyping Detection of the TCF7L2 polymorphisms described by Grant et al. [1] was done using the TaqMan assay (Applied Biosystems, Forster City, CA, USA) in the German population. The TaqMan genotyping reaction was amplified on a GeneAmp PCR system 7000, and fluorescence was detected on an ABI PRISM 7000 sequence detector (Applied Biosystems). As a quality standard, we randomly included six positive (two homozygous wild-type allele carriers, two heterozygous and two homozygous risk allele carriers) and two negative (all components excluding DNA) sequenced controls in each TaqMan reader plate. Because all controls were correctly identified, we assumed that the genotyping error rate of this method did not exceed 0.3% [23].In the Dutch population, only rs7903146 was determined using an ABI PRISM 7900HT sequence detector (Applied Biosystems).
###end p 42
###begin p 43
###xml 0 4 0 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OGTT</bold>
###xml 21 33 <span type="species:ncbi:9606">participants</span>
###xml 286 298 <span type="species:ncbi:9606">participants</span>
OGTT At 08:00 hours, participants ingested a solution containing 75 g glucose. Venous blood samples were obtained at 0, 30, 60, 90 and 120 min for determination of plasma glucose, insulin and C-peptide concentrations and 0, 30 and 120 min for determination of GLP-1 concentrations. The participants did not take any medication known to affect glucose tolerance or insulin sensitivity. Tests were performed after an overnight fast of 12 h.
###end p 43
###begin p 44
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Combined IVGTT and hyperinsulinaemic&#8211;euglycaemic clamp</bold>
###xml 428 429 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 447 452 <span type="species:ncbi:9606">human</span>
Combined IVGTT and hyperinsulinaemic-euglycaemic clamp After an overnight fast and after baseline samples had been obtained, 0.3 g/kg bodyweight of a 20% (vol./vol.) glucose solution was given at time 0. Blood samples for the measurement of plasma glucose, plasma insulin and C-peptide were obtained at 2, 4, 6, 8, 10, 20, 30, 40, 50 and 60 min. After 60 min, a priming dose of insulin was given followed by an infusion (40 mU/m2) of short-acting human insulin for 120 min. A variable infusion of 20% glucose was started to maintain the plasma glucose concentration at 5.5 mmol/l. Blood samples for the measurement of plasma glucose were obtained at 5 min intervals throughout the clamp.
###end p 44
###begin p 45
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hyperglycaemic clamp</bold>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 78 90 <span type="species:ncbi:9606">participants</span>
###xml 114 126 <span type="species:ncbi:9606">participants</span>
###xml 168 180 <span type="species:ncbi:9606">participants</span>
###xml 296 308 <span type="species:ncbi:9606">participants</span>
Hyperglycaemic clamp Hyperglycaemic clamps were performed at 10 mmol/l in all participants. The Dutch NGT and IGT participants underwent a 3 h clamp. In the German NGT participants, the clamp lasted for 2 h followed by the GLP-1 and arginine stimulation (see below). After an overnight fast, the participants received an i.v. glucose bolus to acutely raise glucose levels to 10 mmol/l. Plasma glucose levels were measured at the appropriate intervals to maintain a constant plasma glucose during the clamp. Blood samples for insulin were drawn at 2.5 min intervals during the first 10 min of the clamp and at 10-20 min intervals during the remainder. Exact details of the clamping procedures in the different study groups have been described previously [15, 18, 19].
###end p 45
###begin p 46
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Combined hyperglycaemic clamp</bold>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 362 364 362 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 368 370 368 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 671 672 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 908 914 908 914 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 982 988 982 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1074 1086 1074 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Open circles</italic>
###xml 1091 1105 1091 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">closed circles</italic>
###xml 1117 1120 1117 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIR</italic>
###xml 1145 1150 1145 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrow</italic>
###xml 1187 1188 1187 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1419 1426 1419 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Methods</xref>
###xml 914 1483 914 1483 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Associations between the genotypes of rs7903146 polymorphism in the <italic>TCF7L2</italic> gene with insulin secretion during a hyperglycaemic clamp in 73 German participants. <italic>Open circles</italic> CC; <italic>closed circles</italic> CT and TT. <italic>AIR</italic> Acute insulin response. <italic>Arrow</italic> Administration of 5&#160;g arginine. The <italic>p</italic> values show the differences for first and second phases of glucose-induced insulin secretion, first and second phases of GLP-1-induced insulin secretion and acute insulin secretory response to arginine (AIR) (for calculation see &#8216;<xref rid="Sec2" ref-type="sec">Methods</xref>&#8217;; insulin secretion is adjusted for insulin sensitivity)</p>
###xml 914 1483 914 1483 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Associations between the genotypes of rs7903146 polymorphism in the <italic>TCF7L2</italic> gene with insulin secretion during a hyperglycaemic clamp in 73 German participants. <italic>Open circles</italic> CC; <italic>closed circles</italic> CT and TT. <italic>AIR</italic> Acute insulin response. <italic>Arrow</italic> Administration of 5&#160;g arginine. The <italic>p</italic> values show the differences for first and second phases of glucose-induced insulin secretion, first and second phases of GLP-1-induced insulin secretion and acute insulin secretory response to arginine (AIR) (for calculation see &#8216;<xref rid="Sec2" ref-type="sec">Methods</xref>&#8217;; insulin secretion is adjusted for insulin sensitivity)</p></caption>
###xml 1483 1483 1483 1483 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2007_753_Fig1_HTML" id="MO1"/>
###xml 908 1483 908 1483 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="47">Associations between the genotypes of rs7903146 polymorphism in the <italic>TCF7L2</italic> gene with insulin secretion during a hyperglycaemic clamp in 73 German participants. <italic>Open circles</italic> CC; <italic>closed circles</italic> CT and TT. <italic>AIR</italic> Acute insulin response. <italic>Arrow</italic> Administration of 5&#160;g arginine. The <italic>p</italic> values show the differences for first and second phases of glucose-induced insulin secretion, first and second phases of GLP-1-induced insulin secretion and acute insulin secretory response to arginine (AIR) (for calculation see &#8216;<xref rid="Sec2" ref-type="sec">Methods</xref>&#8217;; insulin secretion is adjusted for insulin sensitivity)</p></caption><graphic position="anchor" xlink:href="125_2007_753_Fig1_HTML" id="MO1"/></fig>
###xml 249 254 <span type="species:ncbi:9606">human</span>
###xml 1060 1072 <span type="species:ncbi:9606">participants</span>
Combined hyperglycaemic clamp This hyperglycaemic clamp combined with GLP-1 and arginine administration was performed as previously described [15, 20-22]. After 120 min of hyperglycaemic clamp at 10 mmol/l, a bolus of GLP-1 (0.6 pmol/kg) was given (human GLP-1(7-36)amide; Poly Peptide, Wolfenbuttel, Germany) followed by a continuous GLP-1 infusion (1.5 pmol kg-1 min-1) during the next 80 min. At 180 min, a bolus of 5 g arginine hydrochloride (Pharmacia & Upjohn, Erlangen, Germany) was injected over 45 s while the GLP-1 infusion was continued. Blood for the measurement of glucose, insulin, proinsulin and C-peptide was obtained during the time-points shown in Fig. 1. This clamp allows measurement of different aspects of stimulus secretion coupling: first and second phases of glucose-induced insulin secretion, GLP-1-induced insulin secretion, and the response to additional arginine administration. Fig. 1Associations between the genotypes of rs7903146 polymorphism in the TCF7L2 gene with insulin secretion during a hyperglycaemic clamp in 73 German participants. Open circles CC; closed circles CT and TT. AIR Acute insulin response. Arrow Administration of 5 g arginine. The p values show the differences for first and second phases of glucose-induced insulin secretion, first and second phases of GLP-1-induced insulin secretion and acute insulin secretory response to arginine (AIR) (for calculation see 'Methods'; insulin secretion is adjusted for insulin sensitivity)
###end p 46
###begin p 47
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 160 172 160 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Open circles</italic>
###xml 177 191 177 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">closed circles</italic>
###xml 203 206 203 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIR</italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrow</italic>
###xml 273 274 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 505 512 505 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Methods</xref>
###xml 146 158 <span type="species:ncbi:9606">participants</span>
Associations between the genotypes of rs7903146 polymorphism in the TCF7L2 gene with insulin secretion during a hyperglycaemic clamp in 73 German participants. Open circles CC; closed circles CT and TT. AIR Acute insulin response. Arrow Administration of 5 g arginine. The p values show the differences for first and second phases of glucose-induced insulin secretion, first and second phases of GLP-1-induced insulin secretion and acute insulin secretory response to arginine (AIR) (for calculation see 'Methods'; insulin secretion is adjusted for insulin sensitivity)
###end p 47
###begin p 48
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analytical procedures</bold>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 828 831 822 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 681 693 <span type="species:ncbi:9606">participants</span>
Analytical procedures Plasma glucose was determined as previously described [14, 17, 20, 21]. GLP-1 was determined during the OGTT at baseline, 30 and 120 min. GLP-1 immunoreactivity was determined using an RIA specific for the C-terminus of the peptide [24]. Samples were stored at -80degreesC. The assay measures the sum of the intact peptide plus the primary metabolite, GLP-1(9-36)amide using the polyclonal anti-GLP-1 antibody 89390 and synthetic GLP-1(7-36)amide as standard.Plasma insulin and C-peptide concentrations in the German cohort were measured by a microparticle enzyme immunoassay (Abbott, Wiesbaden, Germany) and an RIA (Byk-Santec, Dietzenbach, Germany). In the participants from the Netherlands, insulin was measured using an in-house competitive RIA employing a polyclonal anti-insulin antibody (Caris 46), 125I-labelled insulin (IM 166; Amersham, Roosdaal, the Netherlands) as a tracer and regular insulin (Humulin; Eli Lilly, Indianapolis, IN, USA) as a standard.
###end p 48
###begin p 49
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Calculations</bold>
###xml 128 130 128 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CP</sub>
###xml 134 137 134 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Glc</sub>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1716 1718 1716 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
Calculations Insulin secretion in the OGTT was assessed by calculating the AUC for C-peptide divided by the AUC for glucose (AUCCP/AUCGlc). AUCs were determined by the trapezoidal method. Furthermore, insulin secretion was calculated as insulin:glucose ratio by dividing (insulin at 30 min-insulin at 0 min) by (glucose at 30 min-glucose at 0 min). Insulin sensitivity during the OGTT was estimated from glucose and insulin values as proposed by Matsuda and DeFronzo [25].Insulin secretion during the IVGTT was calculated as the sum of C-peptide levels during the first 10 min after glucose administration. Insulin sensitivity during the hyperinsulinaemic-euglycaemic clamp was calculated by dividing the average glucose infusion rate during the last 40 min of the clamp by the average plasma insulin concentration during the same time interval.Insulin secretion during the hyperglycaemic clamp was calculated using insulin levels determined during the clamp. The first phase of insulin secretion was defined as the sum of the insulin levels during the first 10 min of the clamp. The second phase of insulin secretion was defined as the mean of the insulin values during the last 40 min (80-120 min, NGT group, Germany) or the last 30 min (150-180 min, NGT and IGT groups, the Netherlands) of the clamp.In the combined hyperglycaemic clamp with GLP-1 and arginine administration, first-phase GLP-1-induced insulin secretion was defined as the mean of the 125 and 130 min insulin levels, second-phase GLP-induced insulin secretion (plateau) was defined as the mean of the 160-180 min insulin levels. The acute insulin response to arginine was calculated as the mean of 182.5 and 185 min minus 180 min insulin levels [21].The insulin sensitivity index was determined by relating the glucose infusion rate to the plasma insulin concentration during the last 40 min (NGT, Germany) or 30 min of the clamp.
###end p 49
###begin p 50
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Statistical analysis</bold>
###xml 237 238 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W</italic>
###xml 743 744 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 625 637 <span type="species:ncbi:9606">participants</span>
Statistical analysis Data are given as means +/- SEM. Non-normally distributed parameters were logarithmically transformed to approximate linearity for statistical comparison. Distribution was tested for normality using the Shapiro-Wilk W test. Differences in anthropometrics and metabolic characteristics between genotypes were tested using ANOVA for the three genotype groups. The secretion indices were compared using multivariate regression models. In these models the trait was the dependent variable whereas age, sex, insulin sensitivity and genotype were the independent variables. Due to the relatively low number of participants who were homozygous for the rare alleles in the hyperglycaemic clamp group, a dominant model was used. A p value of <0.05 was considered to be statistically significant. The statistical software package JMP (SAS Institute, Cary, NC, USA) was used.
###end p 50
###begin title 51
Results
###end title 51
###begin p 52
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genetic variants in the TCF7L2 gene</bold>
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM1">1</xref>
Genetic variants in the TCF7L2 gene The SNPs described in the paper of Grant et al. [1] had an allelic frequency of the minor allele of 30% (rs7903146), 28% (rs12255372), 31% (rs7901695), 46% (rs11196205) and 45% (rs7895340) in our population. These polymorphisms were all in Hardy-Weinberg equilibrium and in linkage disequilibrium (Electronic supplementary material Table 1).
###end p 52
###begin p 53
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OGTT: glucose tolerance, insulin secretion, insulin sensitivity and GLP-1 levels</bold>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 216 217 216 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 284 286 284 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CP</sub>
###xml 290 293 290 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Glc</sub>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 803 809 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1015 1016 1015 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1173 1179 1173 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1192 1193 1192 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 99 111 <span type="species:ncbi:9606">participants</span>
###xml 339 351 <span type="species:ncbi:9606">participants</span>
###xml 492 504 <span type="species:ncbi:9606">Participants</span>
###xml 733 745 <span type="species:ncbi:9606">participants</span>
###xml 841 853 <span type="species:ncbi:9606">participants</span>
OGTT: glucose tolerance, insulin secretion, insulin sensitivity and GLP-1 levels The percentage of participants with IGT was significantly higher in carriers of the risk allele for rs7903146 (p = 0.007), rs12255372 (p = 0.02) and rs7901695 (p = 0.02).Insulin secretion assessed as AUCCP/AUCGlc during the OGTT was significantly reduced in participants with the risk alleles for rs7903146 and rs12255372 in the additive and dominant model both unadjusted and adjusted for relevant covariates. Participants with the risk allele for rs7901695 had a significantly decreased insulin secretion in the additive model (p = 0.02) (Table 1).Insulin sensitivity, estimated by the index of Matsuda and DeFronzo [25], was significantly higher in participants carrying the risk alleles for rs7903146 and rs1255372 in TCF7L2 (Table 1).In a subgroup of 155 participants we measured GLP-1 concentrations at baseline, at 30 min and 120 min after oral ingestion of 75 g glucose. The anthropometric characteristics are shown in (Table 1). Neither basal GLP-1 plasma levels nor GLP-1 levels during the OGTT significantly differed between the genotypes in any of the above-described SNPs in the TCF7L2 gene (Table 2).
###end p 53
###begin p 54
###xml 0 113 0 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Combined IVGTT and hyperinsulinaemic&#8211;euglycaemic clamp: glucose-induced insulin secretion and insulin sensitivity</bold>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 765 766 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 548 560 <span type="species:ncbi:9606">participants</span>
Combined IVGTT and hyperinsulinaemic-euglycaemic clamp: glucose-induced insulin secretion and insulin sensitivity C-peptide and insulin values during the IVGTT were not significantly different between the genotypes in any of the above-described SNPs in the TCF7L2 gene. Table 3 shows the results for rs7903146 in the additive and dominant model adjusted for relevant covariates. Including the glucose tolerance status as an additional co-variate in the model did not affect the results. Interestingly, a lower insulin secretion in this subgroup of participants could be demonstrated when insulin secretion was calculated from the OGTT as described above (Table 3). Insulin sensitivity measured with the clamp technique was not affected by any of the genotypes (all p > 0.4).
###end p 54
###begin p 55
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hyperglycaemic clamp: glucose-, GLP-1- and arginine-induced insulin secretion and insulin sensitivity</bold>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 696 697 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 722 723 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 849 850 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 873 874 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 899 900 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1027 1028 1027 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 1038 1039 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1206 1212 1206 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1220 1221 1220 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
Hyperglycaemic clamp: glucose-, GLP-1- and arginine-induced insulin secretion and insulin sensitivity First- and second-phase insulin secretion during the hyperglycaemic clamp were not significantly different between carriers and non-carriers of the risk allele for rs7903146 (Table 4) in any of the three populations from the Netherlands and from Germany. The other four SNPs in TCF7L2 which were described above were determined in the German population only and were not associated with glucose-induced insulin secretion (data not shown) during the hyperglycaemic clamp.The first phase of GLP-1-induced insulin secretion was significantly reduced in carriers of the risk alleles for rs7903146 (p = 0.03) and rs12255372 (p = 0.02). In addition, we found significant differences in the second phase of GLP-1-induced insulin secretion for rs7903146 (p = 0.006), rs12255372 (p = 0.005) and rs7901695 (p = 0.02) with carriers of the risk alleles having a significantly lower second phase of GLP-1-induced insulin secretion. Table 4 and Fig. 1 show the results for SNP rs7903146.In contrast to GLP-1-induced insulin secretion, arginine-induced insulin secretion was not affected by any of the analysed SNPs in TCF7L2 (Table 4).
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 837 843 837 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 283 295 <span type="species:ncbi:9606">participants</span>
The variants in TCF7L2 described by Grant et al. [1] that mediate an increased risk of type 2 diabetes have been found to be associated with reduced insulin secretion [6, 7, 9, 10]. We could confirm this reduced insulin secretion in our study in a group of 1,110 German non-diabetic participants using C-peptide levels during an OGTT. Unexpectedly, the i.v. application of glucose during an IVGTT did not affect insulin secretion in carriers of the risk alleles for SNPs in TCF7L2. The same results were obtained using i.v. glucose challenge during a hyperglycaemic clamp in subgroups of the German population and a population from the Netherlands. The observed different results between an orally and i.v. administered glucose challenge generate the hypothesis that incretin-induced insulin secretion is affected by the variants in the TCF7L2 gene. Possible mechanisms explaining these findings include impaired incretin production or incretin signalling.
###end p 57
###begin p 58
To address this issue we first measured basal GLP-1 concentrations and GLP-1 response during an OGTT. None of the tested variants that have been shown in the literature to exert a reproducible effect on type 2 diabetes were associated with basal GLP-1 levels or with GLP-1 response during the OGTT.
###end p 58
###begin p 59
###xml 326 332 326 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 358 370 <span type="species:ncbi:9606">participants</span>
Furthermore, we combined the hyperglycaemic clamp with additional GLP-1 infusion to measure GLP-1-induced insulin secretion. Both acute (so called first phase) and prolonged (so called second phase) GLP-1-induced insulin secretion during the hyperglycaemic clamp were significantly impaired in carriers of the risk alleles in TCF7L2. These data suggest that participants carrying the risk alleles have an impaired insulin secretion due to an impairment of the GLP-1 signalling chain.
###end p 59
###begin p 60
###xml 130 133 130 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT</italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 411 417 411 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
The putative molecular mechanism for this finding is not clear. As the transcription factor TCF7L2 plays an essential role in the WNT signalling pathway [14], which on the one hand is required for a normal development of the pancreas and the pancreatic islets [26] and on the other hand is crucial for the regulation of GLP-1 expression and secretion in intestinal L cells [14]. In theory, polymorphisms in the TCF7L2 gene might therefore through alteration of the WNT signalling pathway directly affect beta cell growth, beta cell differentiation and beta cell function. Furthermore insulin secretion might also be affected indirectly via the enteroinsular axis either through an impaired overall GLP-1 secretion or through a defective or dysfunctional GLP-1-induced insulin secretion. An impaired or dysfunctional GLP-1 effect might result first in a reduced postprandial insulin secretion and second, might influence stimulation of beta cell growth and beta cell differentiation.
###end p 60
###begin p 61
###xml 303 309 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1055 1057 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1076 1082 1076 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
Our data show that basal and glucose-induced GLP-1 secretion during the OGTT were not affected by any of the analysed SNPs, whereas the first and second phases of GLP-1-induced insulin secretion were significantly reduced in carriers of the risk alleles in three of the five above-described SNPs in the TCF7L2 gene, among them rs7903146, which is most strongly associated in the literature with type 2 diabetes [1, 6, 9, 12, 13]. The finding that basal and glucose-stimulated GLP-1 secretion were not influenced by the TCF7L2 polymorphisms indicates that a reduced GLP-1 secretion is not likely to explain the impaired insulin secretion in carriers of the risk genotypes, although it can not fully exclude an effect of these SNPs on GLP-1 levels. First, by measuring total GLP-1 levels, we may have missed a subtle defect in GLP-1 secretion, which may have been detected by measuring the active form of GLP-1. Second, systemic GLP-1 levels may not adequately reflect the level of the active hormone acting in the gut wall on the autonomic nervous system [27]. Third, impaired TCF7L2 activity might tissue-specifically reduce the GLP-1 levels in the brain, which are believed as well to be important for insulin secretion [28].
###end p 61
###begin p 62
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 385 391 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 420 425 <span type="species:ncbi:9606">human</span>
While we have no evidence for reduced GLP-1 secretion we have strong evidence for an impaired GLP-1-induced insulin secretion in carriers of the above-described polymorphisms in TCF7L2. The data show a reduced efficiency of GLP-1 to stimulate insulin secretion in pancreatic beta cells. Alterations of the GLP-1 signalling pathway in beta cells might thereby play a role. Recently the TCF7L2 gene was also identified in human pancreas [14]. Therefore variations in this transcription factor could specifically impair the transcription of genes involved in the incretin signalling chain, resulting in resistance of the pancreatic beta cells to GLP-1.
###end p 62
###begin p 63
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 498 504 498 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 780 786 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
In contrast to the observed reduction in the first and second phases of GLP-1-induced insulin secretion, the arginine-induced insulin secretion was not significantly affected by the analysed SNPs in the TCF7L2 gene. The arginine bolus in the combined hyperglycaemic clamp produces a maximal challenge for the secretory capacity of the beta cell and can be considered as a surrogate for beta cell mass [15, 20]. The SNPs do not affect this maximal insulin secretion, suggesting that the variants in TCF7L2 do not influence beta cell mass, at least in the prediabetic state. In addition, impaired beta cell function may also include the efficiency of the conversion from proinsulin to insulin [21]. However, there was no evidence for this abnormality related to the variants in the TCF7L2 gene during the hyperglycaemic clamp (data not shown).
###end p 63
###begin p 64
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 127 139 <span type="species:ncbi:9606">participants</span>
We also found that insulin sensitivity calculated from the OGTT using an established index [25] was significantly increased in participants carrying the risk alleles for all analysed SNPs in the TCF7L2 gene. This was also described in the study of Florez et al. [9]. When we measured insulin sensitivity with the gold standard, the euglycaemic-hyperinsulinaemic clamp and the hyperglycaemic-hyperinsulinaemic clamp, we found no association of the risk alleles with insulin sensitivity. Taken together, our data suggest that the variants in the TCF7L2 gene do not have a strong effect on insulin sensitivity.
###end p 64
###begin p 65
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 338 344 338 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
In summary, our data show that variations in the TCF7L2 gene are associated with impaired GLP-1-induced insulin secretion. This might be consistent with a state of relative incretin resistance. Increasing the incretin levels by pharmacological tools may thus be a logical therapy to overcome impaired insulin secretion in carriers of the TCF7L2 variants.
###end p 65
###begin title 66
Electronic supplementary material
###end title 66
###begin p 67
Below is the link to the electronic supplementary material.
###end p 67
###begin p 68
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Linkage disequilibrium statistics (D', r2) among the five SNPs reported by Grant et al. [1] in the German population (n=1,110) (PDF 17 KB).
###end p 68
###begin title 69
Acknowledgements
###end title 69
###begin p 70
We thank all the research volunteers for their participation. We gratefully acknowledge the superb technical assistance of A. Bury, H. Luz and L. Bagger. The studies were supported by grants from the Deutsche Forschungsgemeinschaft (KFO 114, Ga 386/9-1), the European Community's FP6 EUGENE2 (LSHM-CT-2004-512013), Merck Sharp & Dohme, the Netherlands Organisation for Health Research and Development, the RIDE programme, the Center for Medical Systems Biology (CMSB) and the Diabetes Research Foundation Amersfoort, the Netherlands.
###end p 70
###begin p 71
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 71
###begin title 72
References
###end title 72
###begin article-title 73
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
###end article-title 73
###begin article-title 74
The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism
###end article-title 74
###begin article-title 75
Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels and type 2 diabetes
###end article-title 75
###begin article-title 76
Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population
###end article-title 76
###begin article-title 77
Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort
###end article-title 77
###begin article-title 78
Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals
###end article-title 78
###begin article-title 79
Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance
###end article-title 79
###begin article-title 80
###xml 112 117 <span type="species:ncbi:9606">women</span>
###xml 122 125 <span type="species:ncbi:9606">men</span>
Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men
###end article-title 80
###begin article-title 81
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program
###end article-title 81
###begin article-title 82
Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample
###end article-title 82
###begin article-title 83
Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2
###end article-title 83
###begin article-title 84
###xml 82 87 <span type="species:ncbi:9606">human</span>
Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes
###end article-title 84
###begin article-title 85
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution
###end article-title 85
###begin article-title 86
TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta
###end article-title 86
###begin article-title 87
###xml 71 77 <span type="species:ncbi:9606">humans</span>
A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility
###end article-title 87
###begin article-title 88
Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test: results with the Botnia clamp
###end article-title 88
###begin article-title 89
Genetic factors and insulin secretion: gene variants in the IGF genes
###end article-title 89
###begin article-title 90
Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose
###end article-title 90
###begin article-title 91
Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects. Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests
###end article-title 91
###begin article-title 92
Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion
###end article-title 92
###begin article-title 93
Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans
###end article-title 93
###begin article-title 94
The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia
###end article-title 94
###begin article-title 95
High-throughput genotyping of single nucleotide polymorphisms using new biplex invader technology
###end article-title 95
###begin article-title 96
###xml 42 47 <span type="species:ncbi:9606">human</span>
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
###end article-title 96
###begin article-title 97
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp
###end article-title 97
###begin article-title 98
Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function
###end article-title 98
###begin article-title 99
Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
###end article-title 99
###begin article-title 100
New ways in which GLP-1 can regulate glucose homeostasis
###end article-title 100
###begin title 101
Abbreviations
###end title 101
###begin p 102
glucagon-like peptide-1
###end p 102
###begin p 103
single nucleotide polymorphism
###end p 103
###begin p 104
transcription factor 7-like 2
###end p 104
###begin p 105
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 105
###begin p 106
The online version of this article (doi:10.1007/s00125-007-0753-6) contains supplementary material, which is available to authorised users.
###end p 106
###begin p 107
An erratum to this article can be found at
###end p 107

